



Vaccines and Global Health: The Week in Review
16 October 2021 :: Issue 628
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents *[click on link below to move to associated content]*

A. Milestones :: Perspectives :: Featured Journal Content

B. Emergencies

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

Milestones :: Perspectives :: Research

.....
.....

SAGE October 2021 meeting highlights

10 October 2021

Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization

4-7 October 2021

(Full report will be published in the Weekly Epidemiological Record on 17.12.2021, and only the wording of the full report should be considered as final)

Report from the WHO department of Immunization, Vaccines and Biologicals

:: The Director's report focused on equity in vaccination especially in the COVID-19 pandemic context which has exposed and exacerbated inequities in access to immunization.

:: Access to COVID-19 vaccines has been extreme in its inequity with high-income countries having administered 35 times more vaccine doses than the low-income countries and the WHO Africa Region countries having only 3% of the population fully vaccinated.

:: While the pandemic has affected childhood immunization programmes across the world, the poorest countries have been affected the most and have been the slowest to recover.

:: Country experiences show that solutions are available and the Immunization Agenda 2030 (IA2030) well lays out the path to recovery and to building resilient immunization programmes.

WHO Regional updates

:: COVID-19 vaccine rollout has started in all WHO regions though the pace of vaccination varies considerably between and within regions, driven largely by the unequal access to vaccine supply. Fifty-six countries found predominantly in the Africa and Eastern Mediterranean regions were unable to achieve the target of fully vaccinating 10% of their populations by September 2021, largely because of lack of vaccine doses.

:: As vaccine supplies improve, the WHO regional offices and partner agencies are supporting country preparedness to overcome existing operational challenges and scale up vaccination to reach the goal of 70% coverage by June 2022.

:: Countries in all regions experienced a decline in coverage with routine childhood vaccination, though the magnitude of the decline and the speed of recovery varied.

:: All the regions have developed or are in the process of developing action plans to operationalize IA2030 in their respective regions. This will provide an opportunity to accelerate recovery and to strengthen the resilience of immunization programmes.

IA2030 update

:: SAGE was presented with the first progress report on the Immunization Agenda 2030, featuring baseline data from 2019-2020, as part of an update on the operationalization of IA2030, including the framework and process for monitoring, evaluation, and accountability.

:: The WHO regional offices have developed regional strategies or frameworks aligned to IA2030, in collaboration with their Member States and regional stakeholders; most have been approved by the respective Regional Committees.

:: Progress was made with the development of the IA2030 governance and coordination process and structures, including the partnership council, the coordination group, and working groups.

:: SAGE will conduct independent annual assessments of progress and provide recommendations for corrective actions to Member States and the relevant Working Groups.

:: SAGE recommended that relevant stakeholders conduct country-by-country analysis of programmatic bottlenecks and challenges to inform corrective actions to be taken at global, regional and national levels.

:: SAGE recommended that countries develop National Immunization Strategies aligned to the IA2030 and Regional Frameworks and establish national monitoring, evaluation, and accountability processes.

Poliomyelitis

:: There has been a substantial drop in wild poliovirus detections in the endemic areas in 2021 and there have been no reported cases since February 2021. SAGE emphasized the need to fully engage program resources to achieve eradication while maintaining or strengthening poliovirus surveillance.

:: SAGE expressed concern regarding ongoing transmission of circulating Vaccine Derived Poliovirus type 2 (cVDPV2), particularly in the African region, the recurrent cVDPV2 outbreaks in Nigeria, and highlighted the need for timely responses.

:: SAGE recommended a cautious approach to withdrawing oral poliovirus vaccine (OPV) from national routine immunization schedules in the pre-eradication period but acknowledged that countries in polio-free regions with high vaccination coverage may consider switching to Inactivated Poliovirus Vaccine (IPV) only schedules, including a 2-dose IPV schedule. Once adequate supply is available, the use of whole-cell pertussis hexavalent vaccines containing IPV will facilitate the use of IPV-only schedules.

:: SAGE endorsed the transition of the novel OPV type 2 vaccine (nOPV2) from initial to wider use under WHO Emergency Use Listing (EUL), based on the findings of the independent safety and genetic stability assessment.

COVID-19

:: Bharat Biotech's COVID-19 Vaccine (COVAXIN) was reviewed by SAGE; a policy recommendation will be issued when the vaccine is Emergency Use listed by WHO.

:: SAGE recommended that moderately and severely immunocompromised persons should be offered an additional dose of all WHO EUL COVID-19 vaccines as part of an extended primary series since these individuals are less likely to respond adequately to vaccination following a standard primary vaccine series and are at high risk of severe COVID-19 disease.

:: For the Sinovac and Sinopharm inactivated vaccines, an additional (third) dose of the homologous vaccine should be offered to persons aged 60 and above as part of an extended primary series. The use of a heterologous platform vaccine for the additional dose may also be considered based on vaccine supply and access considerations. When implementing this recommendation, countries should initially aim at maximizing 2-dose coverage in that population, and thereafter administer the third dose, starting in the oldest age groups.

The global COVID-19 vaccination strategy

:: The global COVID-19 vaccination strategy, previously reviewed by SAGE, provides the goals, the resource requirements, and describes the expected outcomes underlying the vaccination targets set for the end of 2021 and mid-2022.

:: Drawing on SAGE's June 2021 recommendation and advancing it, given the progression of the pandemic, the strategy prioritizes vaccination of high-risk populations and all adults and fully commits to the risk mitigation approach by calling for 70% of the world's population fully vaccinated by mid-2022.

:: The strategy acknowledges the scientific uncertainties and the need for updates as new evidence becomes available.

:: SAGE noted that success in achieving the goals and interim targets of the strategy will require the collective and cohesive actions of all relevant stakeholders.

The RTS,S/AS01 malaria vaccine

:: In a joint session, SAGE and the Malaria Policy Advisory Group (MPAG) reviewed the evidence on the RTS,S/AS01 malaria vaccine and recommended that the vaccine be used for the prevention of P.

falciparum malaria in children living in regions with moderate to high transmission as defined by WHO.

:: The vaccine should be provided in a schedule of 4 doses in children from the age of 5 months to reduce the burden of malaria.

:: Drawing from a growing body of evidence, countries may consider providing the RTS,S/AS01 vaccine seasonally, with a 5-dose strategy in areas with highly seasonal malaria or areas with perennial malaria transmission with seasonal peaks. When countries choose the seasonal deployment of the RTS,S/AS01 vaccine, they are strongly encouraged to document their experience, including the vaccine effectiveness, feasibility, and occurrence of any adverse events, to feed into future guidance updates.

:: RTS,S/AS01 introduction should be considered in the context of comprehensive national malaria control plans.

:: The recommendation is based on results from an ongoing pilot programme in Ghana, Kenya and Malawi that has vaccinated more than 800 000 children since 2019. The evaluation results show that the vaccine has a favourable safety profile, is effective, and led to a substantial reduction in life-threatening severe malaria, even in settings with good coverage with insecticide treated nets, and access to treatment.

:: The pilot programme also showed that there is high demand for the vaccine, and that it can be delivered effectively through the routine child immunization programmes without affecting the uptake of other vaccines or malaria interventions. Because of its high uptake and coverage, the vaccine has been able to reach vulnerable children who are currently not protected by other malaria control interventions.

Influenza vaccines

:: Influenza causes an estimated > 1 bn cases of infection, including 3-5 million episodes of severe disease and 290,000 – 650,000 deaths annually.

:: SAGE recommends that all countries consider implementing seasonal influenza vaccination based on the burden and epidemiology of disease, the cost-effectiveness of vaccination, competing public health priorities, and programmatic feasibility.

:: For countries considering the initiation or expansion of programmes for seasonal influenza vaccination, SAGE recommended that the following target groups should be considered for vaccination in no particular order of priority: health workers, individuals with specific chronic medical conditions, older adults and pregnant women.

:: Countries may consider additional (sub)populations for vaccination such as children and individuals at high risk of severe influenza living in congregate-living setting such as prisons, long-term care facilities, refugee camps, asylum seekers and group homes.

:: Vaccination in the current and prior season afforded better protection than not being vaccinated or being vaccinated in the prior season only, although protection from vaccination in the current and prior season was attenuated, particularly for the H3N2 sub-type, when compared with vaccination in the current season alone. SAGE continues to recommend annual seasonal influenza vaccination for the priority target groups.

:: Limited evidence on co-administration of inactivated seasonal influenza vaccines with COVID-19 vaccines showed no increased adverse events. Since the adult age groups targeted for seasonal

influenza vaccination are also at risk for developing severe COVID-19, co-administration of an inactivated seasonal influenza vaccine and any WHO emergency use listed COVID-19 vaccine is acceptable and will maximize the uptake of both vaccines.

:: In the context of the COVID-19 pandemic, SAGE continues to recommend the prioritization of health workers and older adults as target groups for seasonal influenza vaccination during the COVID-19 pandemic, and countries should also consider prioritization of pregnant women

Behavioural and social drivers of vaccine uptake

:: New evidence, tools, and guidance on 'Behavioural and social drivers (BeSD) of vaccine uptake' to support programmes to assess and address reasons for under-vaccination were presented to SAGE.

:: SAGE recognized the importance for measuring factors contribute to low uptake and took note of the evidence-informed framework for measuring behavioural and social drivers.

:: SAGE recommended the systematic gathering and use of data on BeSD to assess the reasons for low uptake, periodic monitoring of trends.

Hepatitis E vaccine

:: SAGE highlighted the importance of the hepatitis E vaccination to mitigate the impact of outbreaks with the principal aim of protecting pregnant women and noted that those most affected by hepatitis E are underprivileged populations in low-resource settings.

:: SAGE encouraged manufacturers to proceed as quickly as possible with seeking WHO prequalification, this should not preclude the use of the vaccine prior to pre-qualification.

:: SAGE encouraged the continued coordination between key stakeholders and recommended that WHO work with Gavi for inclusion of hepatitis E vaccination for outbreak response and hepatitis E surveillance and diagnostics within its portfolio of support to eligible countries.

.....
.....

TB

Global tuberculosis report 2021

14 October 2021 |

WHO Report :: 57 pages

PDF: <https://apps.who.int/iris/rest/bitstreams/1379788/retrieve>

Overview

Each year, the WHO Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

The 2021 edition of the report has been produced in a new and more web-centric format. This is designed to make the content available in smaller (more "bite-sized") chunks that are easier to read, digest, navigate and use. There is a short and slim report PDF with 30 pages of main content plus six short annexes. This is accompanied by expanded and more detailed digital content on [web pages](#). The total amount of content remains similar to that of previous years.

Please note that direct comparisons between estimates of TB disease burden in the latest report and previous reports are not appropriate. The most recent time-series of estimates are published in this global TB report.

Global TB reports from previous years can be found [here](#).

Top findings and messages in the 2021 report

The COVID-19 pandemic has reversed years of progress in providing essential TB services and reducing TB disease burden. Global TB targets are mostly off-track, although there are some country and regional success stories.

The most obvious impact is a large global drop in the number of people newly diagnosed with TB and reported. This fell from 7.1 million in 2019 to 5.8 million in 2020, an 18% decline back to the level of 2012 and far short of the approximately 10 million people who developed TB in 2020. 16 countries accounted for 93% of this reduction, with India, Indonesia and the Philippines the worst affected. Provisional data up to June 2021 show ongoing shortfalls.

Reduced access to TB diagnosis and treatment has resulted in an increase in TB deaths. Best estimates for 2020 are 1.3 million TB deaths among HIV-negative people (up from 1.2 million in 2019) and an additional 214 000 among HIV-positive people (up from 209 000 in 2019), with the combined total back to the level of 2017. Declines in TB incidence (the number of people developing TB each year) achieved in previous years have slowed almost to a halt. These impacts are forecast to be much worse in 2021 and 2022.

Other impacts include reductions between 2019 and 2020 in the number of people provided with treatment for drug-resistant TB (-15%, from 177 100 to 150 359, about 1 in 3 of those in need) and TB preventive treatment (-21%, from 3.6 million to 2.8 million), and a fall in global spending on TB diagnostic, treatment and prevention services (from US\$ 5.8 billion to US\$ 5.3 billion, less than half of what is needed).

Actions to mitigate and reverse these impacts are urgently required. The immediate priority is to restore access to and provision of essential TB services such that levels of TB case detection and treatment can recover to at least 2019 levels, especially in the most badly-affected countries.

a Officially classified as deaths from HIV/AIDS.

Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic

14 October 2021

The COVID-19 pandemic has reversed years of global progress in tackling tuberculosis and for the first time in over a decade, TB deaths have increased, according to the World Health Organization's 2021 Global TB report.

In 2020, more people died from TB, with far fewer people being diagnosed and treated or provided with TB preventive treatment compared with 2019, and overall spending on essential TB services falling.

"This report confirms our fears that the disruption of essential health services due to the pandemic could start to unravel years of progress against tuberculosis," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "This is alarming news that must serve as a global wake-up call to the urgent need for investments and innovation to close the gaps in diagnosis, treatment and care for the millions of people affected by this ancient but preventable and treatable disease."...

The increase in the number of TB deaths occurred mainly in the 30 countries with the highest burden of TB[1]. WHO modelling projections suggest the number of people developing TB and dying from the disease could be much higher in 2021 and 2022...

WHO estimates that some 4.1 million people currently suffer from TB but have not been diagnosed with the disease or have not officially reported to national authorities. This figure is up from 2.9 million in 2019...

.....
.....

WHO Announces Proposed Members of its Scientific Advisory Group for the Origins of Novel Pathogens (SAGO)

13 October 2021

Following a public call for experts, the World Health Organization (WHO) today announced proposed members of the WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO). The SAGO will advise WHO on the development of a global framework to define and guide studies into the origins of emerging and re-emerging pathogens of epidemic and pandemic potential, including SARS-CoV-2.

"The emergence of new viruses with the potential to spark epidemics and pandemics is a fact of nature, and while SARS-CoV-2 is the latest such virus, it will not be the last," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Understanding where new pathogens come from is essential for preventing future outbreaks with epidemic and pandemic potential, and requires a broad range of expertise. We are very pleased with the calibre of experts selected for SAGO from around the world, and look forward to working with them to make the world safer."

Selected from more than 700 applications, the 26 proposed SAGO members have expertise in a range of areas, including epidemiology, animal health, ecology, clinical medicine, virology, genomics, molecular epidemiology, molecular biology, biology, food safety, biosafety, biosecurity, and public health. The composition of the SAGO reflects geographic and gender diversity.

As per WHO processes, **there will now be a two-week public consultation period** for WHO to receive feedback on the proposed SAGO members and set in place the modalities for the SAGO's first meeting, which is planned to take place following this consultation period. **The final membership to the SAGO is subject to the above-mentioned public consultation period and relevant WHO practices and procedures.**

Functions of the SAGO

In its capacity as an advisory body to WHO, the SAGO will have the following functions:

[1] To advise WHO on the development of a WHO global framework to define and guide studies into the origins of emerging and re-emerging pathogens of epidemic and pandemic potential;
[2] To advise WHO on prioritizing studies and field investigations into the origins of emerging and re-emerging pathogens of epidemic and pandemic potential, in accordance with the WHO global framework described in point (1) above;

1. To provide information and views to assist the WHO Secretariat in the development of a detailed work plan of the SAGO;

2. In the context of SARS-CoV-2 origins:
 - To provide the WHO Secretariat with an independent evaluation of all available scientific and technical findings from global studies on the origins of SARS-CoV-2;
 - To advise the WHO Secretariat regarding developing, monitoring and supporting the next series of studies into the origins of SARS-CoV-2, including rapid advice on WHO's operational plans to implement the next series of global studies into the origins of SARS-CoV-2, as outlined in the Joint WHO-China Global Study of Origins of SARS-CoV-2: China Part report published on 30 March 2021 and advise on additional studies as needed; and
3. To provide additional advice and support to WHO, as requested by the WHO SAGO Secretariat, which may include participation in future WHO-international missions to study the origins of SARS-CoV-2 or for other emerging pathogens.

Public notice of proposed new Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) members

13 October 2021 *Call for consultation*

After careful consideration of all applications submitted to WHO, the following individuals are proposed for membership of the WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO). They are to serve in their personal capacities to represent the broad range of disciplines relevant to emerging and re-emerging pathogens. In evaluating the applications submitted, consideration was given to attaining an adequate distribution of technical expertise, geographical representation and gender balance.

1. **Mr Phillip Alviola** is an Associate Professor at the Animal Biology Division at the Institute of Biological Sciences, University of the Philippines. He is originally from the Philippines.
2. **Dr Abdullah Assiri** is an Assistant Deputy Minister for Preventive Health at the Ministry of Health in Saudi Arabia. He is originally from the Kingdom of Saudi Arabia.
3. **Dr Stuart Blacksell** is a Professor of Tropical Microbiology at the Nuffield Department of Medicine at the University of Oxford. He is originally from Australia.
4. **Dr Inger Damon** is the Director of the Division of High Consequence Pathogens and Pathology at the United States Centers for Disease Control and Prevention. She is originally from the United States of America.
5. **Dr Vladimir Dedkov** is the Deputy Director for Research at the Pasteur Institute in Russia. He is originally from Russia.
6. **Dr Christian Drosten** is a Professor and head of the Institute of Virology at Charité in Germany. He is originally from Germany.
7. **Dr Elmoubasher Farag** is a senior infectious disease epidemiologist and the Head of the Communicable Diseases Control Programs at the Ministry of Public Health in Qatar. He is originally from Sudan.
8. **Dr Thea Fischer** is a Professor of virology at the University of Copenhagen and Head of Clinical Research at Nordsjællands Hospital in Denmark. She is originally from Denmark.
9. **Dr Raman Gangakhedkar** is the Dr C.G. Pandit National Chair at the Indian Council of Medical Research in India. He is originally from India.
10. **Dr Nada Ghosn** is the head of the Epidemiology Surveillance Program and Medical officer for the Directorate of Prevention at the Ministry of Health, Lebanon. She is originally from Lebanon.
11. **Dr Maria Guzman** is the head of the Center for Research, Diagnostic and Reference at the Institute of Tropical Medicine Pedro Kouri in Cuba. She is originally from Cuba.

12. **Dr Christian Happi** is a Professor and director at the African Center of Excellence for Genomics of Infectious Disease (ACEGID), Redeemer's University, Ede, Nigeria. He is originally from Cameroon.
13. **Dr Marion Koopmans** is a Professor and the head of the department of the Viroscience at Erasmus MC. She is originally from the Netherlands.
14. **Dr Sowath Ly** is the Deputy Head of Epidemiology and Public Health Unit at the Institut Pasteur du Cambodge. He is originally from Cambodia.
15. **Dr Jean-Claude Manuguerra** is a research Research Director of the Environment and Infectious Risks Unit, as well as the head for the Emergency Biological Intervention Unit at the Institut Pasteur in France. He is originally from France.
16. **Dr Khin Myint** is the head of the Emerging Virus Research Unit at the Eijkman Institute for Molecular Biology in Jakarta, Indonesia. She is originally from Myanmar.
17. **Dr Carlos M. Morel** is the Director at the Center for Technological Development in Health at the Oswaldo Cruz Foundation (Fiocruz) and Ministry of Health in Brazil. He is originally from Brazil.
18. **Dr Hung Nguyen-Viet** is the co-program leader of Animal and Human Health Program at the International Livestock Research Institute in Kenya. He is originally from Vietnam.
19. **Dr Chinwe Ochu** is the Director of the Prevention Programmes and Knowledge Management at the Nigeria Centre for Disease Control. She is originally from Nigeria.
20. **Dr Masayuki Saijo** is the Director of the Medical Planning Department Sapporo City Health and Welfare Bureau in Sapporo, Japan. He is originally from Japan.
21. **Dr Rosemary Sang** is an advisor and Chief Research Officer at the Centre for Virus Research, Kenya Medical Research Institute (KEMRI), Kenya. She is originally from Kenya.
22. **Dr Katharina Summermatter** is the head of the Biosafety Center and Managing Director of the Biosafety Level 3 Laboratory at the Institute for Infectious Diseases at the University of Berne in Switzerland. She is originally from Switzerland.
23. **Dr Marietjie Venter** is a Professor of the Zoonotic Arbovirus and Respiratory Virus Research Programme at the Centre for Viral Zoonoses, Department of Medical Virology at the University of Pretoria in South Africa. She is originally from South Africa.
24. **Dr Supaporn Wacharapluesadee** is a researcher at the King Chulalongkorn Memorial Hospital, The Thai Red Cross Society and a committee member of Chula School of Global Health, Faculty of Medicine, Chulalongkorn University. She is originally from Thailand.
25. **Dr John Watson** is an Honorary Professor at the Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, as well as a Visiting Professor in the Research Department of Infection and Population Health at the University College of London. He is originally from the United Kingdom.
26. **Dr Yungui Yang** is the Deputy Director at the Beijing Institute of Genomics at the Chinese Academy of Sciences in China. He is originally from China.

Pursuant to WHO's rules and practices, and in order to enhance WHO's management of conflicts of interest, as well as strengthen public trust and transparency in connection with WHO advisory groups involving the provision of technical advice, the names and brief biographies of the individuals selected for SAGO Membership are now disclosed for public notice and comment. Should you wish to comment on any of the individuals, please send your comment to SAGO@who.int with subject, "**Public comments on SAGO members**" by **27 October 2021**.

.....

Editor's Note:

We will selectively include opinion and analysis from major media sources as below, recognizing the continuing extraordinary volume of COVID coverage globally.

Financial Times

October 12, 2021

Opinion The FT View

Vaccinating poorer countries is vital to the recovery

IMF warns uneven pace of immunisation raises risks of economic scarring

The FT editorial board

[Editor's text bolding]

It would be hard to find an example of a government intervention that has done more good than vaccination efforts against coronavirus. As well as the obvious health benefits, immunising as many people as possible — starting with the most vulnerable — has allowed economies to unlock, workers to return to offices and emergency support measures to wind down. That has helped to produce an economic bounceback in the rich world that has more than paid off the amount invested in vaccinations.

Yet as the IMF points out in its World Economic Outlook, published on Tuesday to coincide with the Fund and the World Bank's annual meetings in Washington, **vaccination efforts are shockingly uneven. That will hold back the global economic recovery: poorer countries will lag even further behind** rich ones that have also been better able to use fiscal and monetary stimulus to support their economies. **It is imperative now that rich countries make good on their promises to donate vaccines to the Covax initiative**, which aims to ensure equitable global access. **They should also lean on drugs companies to do their part in ensuring poorer countries gain access to life-saving jabs.**

The IMF warns that the **momentum behind the global recovery has faded**. It rightly notes current supply chain disruptions underline the need for central banks to be "very, very vigilant" over spiralling inflation expectations getting out of hand. But it identifies the fundamental problem as "the continued grip of the pandemic on global society". Not only is this holding back the recovery in international services trade such as tourism, and contact-heavy activities such as hospitality; it is also contributing to the supply chain troubles as coronavirus outbreaks have led to factory shutdowns. Global co-operation to immunise the developing world, then, is not only a humanitarian good but in rich countries' self-interest.

However, only about a fifth of the 850m doses pledged by G7 countries to Covax in June had been delivered by September. It is understandable that governments were reluctant to give away scarce vaccines earlier this year when rich countries themselves were bitterly divided over exporting them to one another. But given the success of rollouts to date, it is now largely vaccine hesitancy rather than supply issues that is holding back take-up among those still unjabbed in rich countries. Now that economies are reopening, export controls should also be eased on medical equipment.

The pace of vaccinations is one of the biggest influences on the IMF's estimates of "medium term scarring" from the pandemic. While, in aggregate, rich economies are expected to be 0.9 per cent bigger than before the pandemic by 2024, poorer countries, excluding China, are expected still to be 5.5 per cent smaller — undoing much of the poverty reduction over the past decade. The US, thanks to

extraordinary stimulus efforts, is expected to have “negative scarring” as Covid-19 accelerated efforts to renew infrastructure, as well as the green transition.

Vaccine manufacturers, too, have a duty to do more to increase access to their products and lower the cost. While Moderna and BioNTech, which produces a vaccine with Pfizer, have both pledged to move production to Africa, details are still scant and it will take time for such production to come online. As the IMF points out, the longer the pandemic continues, the less able countries will be to keep on spending to offset the continued economic harm. Rich countries got a head start in the race to vaccinate; now, in everybody’s interest, they must redouble their efforts to help others catch up.

.....
.....

WTO -TRIPS

Members pursue convergence for an IP COVID-19 response

World Trade Organization

14 October 2021

At a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 13-14 October 2021, **WTO members noted encouraging exchanges at recent small group discussions and bilateral meetings which helped to identify points of convergence on how to provide a common intellectual property (IP) response to COVID-19.** The chair of the TRIPS Council, Ambassador Dagfinn Sørli of Norway, announced he would continue to consult with members on how to move towards a consensus before the **WTO’s 12th Ministerial Conference (MC12), to be held on 30 November — 3 December**

Members appreciated the opportunities provided by recent small group and bilateral meetings to discuss issues related to the **scope and implementation of the revised TRIPS waiver proposal first put forward by South Africa and India (IP/C/W/669/Rev.1) as well as the proposal for a draft General Council Declaration on the TRIPS Agreement and Public Health in the circumstances of a pandemic (IP/C/W/681) from the European Union, particularly with regards the use of current TRIPS compulsory licensing provisions.**

Some delegations said that the results of those discussions were "encouraging" and helped to identify "important points of convergence". Others said that further conversations that move the TRIPS Council towards evidence-based and pragmatic solutions should be the next step guiding their discussions at this critical juncture, with only seven weeks left before MC12.

Co-sponsors of the TRIPS waiver proposal reiterated that this initiative should be an integral part of any successful MC12 outcome and urged members to move beyond the binary approach between the two proposals on the table and engage constructively to secure consensus. Members also underlined the importance of aligning the facilitation process under Ambassador David Walker of New Zealand and the work by the TRIPS Council chair, so that a comprehensive package on trade and health leading to a multilateral and horizontal response to the COVID-19 pandemic can be achieved.

Some members noted the consensus-based nature of the WTO and the complexity of the issues involved, and flagged the risk of not achieving an outcome unless delegations are able to make some

real compromises. **A positive and meaningful outcome at MC12 on the IP response to the pandemic would not only send a powerful message of global solidarity, but would also be proof that the WTO has the ability to respond to a major global crisis, these members added...**

Members noted the WTO Secretariat's updated compilation "[COVID-19: Measures Regarding Trade-Related Intellectual Property Rights](#)" that is available on the WTO website. This non-exhaustive list, compiled from official sources, represents an informal situation report and an attempt to provide transparency with respect to measures related to intellectual property rights taken in the COVID-19 context. The chair stressed that the list is updated continuously, even if the rate at which new measures are brought to the Secretariat's attention is slowing down...

.....
.....

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

16 Oct 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 239M total confirmed cases; 4.9M total confirmed deaths

Global vaccines administered: 6.64B

Number of Countries: 29 [29 week ago]

COVAX Allocations Round 4-6 (Number of Doses): 120M [120M week ago]

COVAX Delivered (Number of Doses): 110M [98M week ago]

Other Delivered (Number of Doses): 190M [160M week ago]

Total Delivered (Number of Doses): 300M [260M week ago]

Total Administered (Number of Doses): 240M [230M week ago]

.....
.....

World Bank Vaccine Operations Portal

<https://www.worldbank.org/en/who-we-are/news/coronavirus-covid19/world-bank-support-for-country-access-to-covid-19-vaccines>



*As of October 8, 2021, the **World Bank approved operations to support vaccine rollout in 61 countries amounting to \$5.8 billion. See the latest project financing, project documents and procurement information [in the list here](#). More information will be shared here as it becomes available.***

.....
.....

Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

A [joint initiative](#) from the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-

income countries. Website accessed **16 Oct 2021**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).



.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 16 Oct 2021

Confirmed cases ::	239 437 517	[236 599 025 week ago]
Confirmed deaths ::	4 879 235	[4 831 486 week ago]
Vaccine doses administered:	6 495 672 032	[6 262 445 422 week ago]

.....

Weekly epidemiological update on COVID-19 - 13 October 2021


Overview

Globally, the numbers of weekly COVID-19 cases and deaths has continued to decline since late August. Over 2.8 million new cases and over 46 000 new deaths were reported during the week of 4 to 10 October 2021, representing a 7% and 10% decrease respectively, as compared to the previous week. Apart from the European Region, which reported a 7% increase in new weekly cases, all the other regions reported a decline. The largest decrease in new weekly cases was reported from the African Region (32%), followed by the Western Pacific Region (26%). The cumulative number of confirmed cases reported globally is now over 237 million and the cumulative number of deaths is over 4.8 million.

The number of new weekly deaths reported, showed a large (>10%) decline for all regions except for the European Region, which reported an increase of 11% as compared to the previous week. The largest decline in weekly deaths was reported from the Western Pacific and the African Regions, with both showing a 34% decline as compared to the previous week.

In this edition, we provide an update on SARS-CoV-2 Variants of Concern (VOCs) Alpha, Beta, Gamma and Delta along with their geographical distribution.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 10 October 2021**




















**See [Annex 2: Data, table and figure notes](#)

.....

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 29 September 2021

For 23 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[Full scale view available at title link above]

Vaccines				Guidance Document 29 September 2021					
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process									
	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
1.	 BioNTech Manufacturing GmbH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized: Additional sites: – Baxter Oncology GmbH Germany (DP) – Novartis Switzerland – Mibe (Dermapharm) Germany (DP) – Delpharm, Saint-Remy FRANCE (DP) – Shelf life extension: 09 months at -70 to -90°C Diluent suppliers: – Pfizer Perth, Australia/Fresenius Kabi, USA	31/12/2020 30/06/2021 08/07/2021 16/07/2021 17/09/2021 20/09/2021
			USFDA				✓	Finalized: – Pharmacia & Upjohn, Kalamazoo (DP)PGS McPherson (DP)	18/06/2021 16/07/2021 16/07/2021
2.		AZD1222 Vaxzevria	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Core data finalized	16 April 2021
							✓	Finalized: Additional sites: – SK-Catalent – Wuxi (DS) – Chemo Spain – Amylin Ohio US (DP)	16 April 2021 30 April 2021 04 June 2021 23 July 2021
3.	 AstraZeneca, AB	AZD1222 Vaxzevria	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
4.		AZD1222 Vaxzevria	Japan MHLW/PMDA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized Additional site	09 July 2021 TBC
5.		AZD1222 Vaxzevria	Australia TGA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized Additional site: Thailand	09 July 2021 TBC
6.	 Serum Institute of India Pvt. Ltd	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
7.	 Janssen-Cilag International NV	Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data finalized (US +NL sites)	12 March 2021
							Additional sites: - Merck, Durham, UK (DS) - Merck, West Point/PA (DP)	Finalized – Aspen RSA (DP) – Catalent Agnani Italy (DP) - Future submission - Future submission	-25 June 2021 -02 July 2021 - As submitted - As submitted
Vaccines				Guidance Document 29 September 2021					
8.	 Moderna Biotech	mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)		✓	✓	Finalized	30 April 2021
			USFDA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized ModernaTx, Norwood (DS) - Catalent Indiana, LLC (DP) - Lonza Biologics, Inc. Portsmouth, USA (DS) - Baxter, Bloomington, USA (DP)	06 August 2021
9.	 Beijing Institute of Biological Products Co., Ltd. (BIBP)	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized 2 and 5 dose presentation (new manufacturing site)	07 May 2021 TBC
10.	 Sinovac Life Sciences Co., Ltd. Sinovac Life Sciences Co., Ltd.	COVID-19 Vaccine (Vero Cell), Inactivated/ Coronavac™	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized 2 dose presentation	01 June 2021 30 September 2021
11.	 The Gamaleya National Center	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission incomplete.	On hold, awaiting completion of rolling submission	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
12.	 Bharat Biotech, India	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/ COVAXIN	DCGI	Whole-Virion Inactivated Vero Cell	✓	✓	Rolling data started 06 July 2021	Ongoing	October 2021
13.	 Sinopharm / WIBP ²	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓	Rolling data started 23 July 2021	Ongoing	To be confirmed (TBC)
14.	 CanSinoBio	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data started 09 August 2021	Ongoing	TBC
15.	 Novavax	NVX-CoV2373/Covovax	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	✓	Rolling data starting in August 2021	Ongoing	TBC
16.	 SANOFI	CoV2 preS dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓		Rolling data started 30 July 2021	Ongoing	TBC
17.	 Serum Institute of India Pvt. Ltd	NVX-CoV2373/Covovax	DCGI	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	10 August 2021	Rolling data starting in August 2021	Ongoing	TBC
18.	 Clover Biopharmaceuticals	SCB-2019	NMPA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	✓	✓	Rolling data starting 20 September	Ongoing	TBC
19.	 CureVac	Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/COV050101	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Planned for Q4 of 2021, at request of the applicant.			
20.	 Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				

Vaccines				Guidance Document 29 September 2021				
21.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	Response to 2 nd EOI sent 29 Jan 2021. Additional information requested.			
22.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development			
23.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus, Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	Awaiting information on strategy and timelines for submission.			

1. Beijing Institute of Biological Products Co Ltd
2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.
** Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made
*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

.....

COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca

Press Releases

[AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial](#)

11 October 2021

:: Trial met primary endpoint

:: AZD7442 is the only long-acting antibody combination shown to both prevent and treat COVID-19

BioCubaFarma – Cuba

Últimas Noticias - *[Website not responding at inquiry; receiving 403-Forbidden]*

CanSinoBIO

News - *[Website not responding at inquiry]*

Clover Biopharmaceuticals - China

News - *No new digest announcements identified*

Curevac [Bayer Ag – Germany]

News

[CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology](#)

October 12, 2021

:: COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK

:: First-generation vaccine candidate, CVnCoV, to be withdrawn from regulatory review due to potential overlap with approval timelines for a second-generation candidate

Gamaleya National Center

Latest News and Events - *No new digest announcements identified [See Russia/RFID below]*

IMBCAMS, China

Home - *No new digest announcements identified*

Janssen/JNJ

Press Releases

Oct 15, 2021 United States

[Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee](#)

:: Recommendation informed by Phase 3 findings showing a booster increased protection to 94 percent against moderate to severe/critical COVID-19 in the U.S.

:: Johnson & Johnson COVID-19 vaccine, when given as a booster or primary dose, was generally well-tolerated

:: FDA to decide whether to authorize a booster dose in the coming days

Moderna

Press Releases

October 14, 2021

[Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna's COVID-19 Vaccine in the U.S.](#)

:: Positive unanimous vote for mRNA-1273 booster at the 50 µg dose level for individuals aged 65 and older as well as individuals aged 18 through 64 at high risk of contracting COVID-19 at least 6 months after completion of the primary series

:: Company estimates that booster at the 50 µg dose level could result in up to 1 billion additional doses

October 12, 2021

[Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna's COVID-19 Vaccine for Low Income Countries in First Half of 2022](#)

Novavax

Press Releases

[Complete PREVENT-19 Phase 3 Clinical Trial Results Manuscript for COVID-19 Vaccine Posted to medRxiv](#) Oct 11, 2021

[<https://www.medrxiv.org/content/10.1101/2021.10.05.21264567v1>]

Pfizer

Recent Press Releases - No new digest announcements identified

Sanofi Pasteur

Press Releases

[Update from Sanofi regarding Kevzara® \(sarilumab\): Supply constraints anticipated until early 2022](#)

October 12, 2021

:: Sanofi is currently experiencing an increase in worldwide demand for sarilumab (Kevzara®) due to an increase in the global demand for IL-6 receptor blockers and the temporary tocilizumab shortage.¹

:: Due to this exceptional demand, supply for all four formats of sarilumab (150mg or 200mg pre-filled syringe or auto-injector) is expected to be constrained until early 2022 based on current forecasts.

:: Various country and global health authorities have recommended IL-6 receptor blockers for the treatment of patients with severe or critical COVID-19. Sarilumab is not approved or authorized for emergency use for the treatment of COVID-19 anywhere in the world, and Sanofi will continue to prioritize access for indicated patients with rheumatoid arthritis.

:: Sanofi is working diligently to manage supply to minimize the impact of this increase in demand, and we are committed to proactive and timely communication as the situation evolves.

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

Press releases for media - No new digest announcements identified

Merck

News releases

[**Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ \(Pneumococcal 15-valent Conjugate Vaccine\) in Individuals 18 Years of Age and Older**](#)

October 15, 2021

[**Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults**](#)

October 15, 2021

SK Biosciences

Press releases - No new digest announcements identified

.....

.....

[**UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 16 Oct 2021**](#)

An overview of information collected from publicly announced bilateral and multilateral supply agreements [agreements view since last week's edition]

**24**vaccines **approved for use** by at least one national regulatory authority ¹**7**vaccines in WHO's **Emergency Use Listing****19.1bn**doses **secured globally****\$2 - \$37**reported vaccine **price range** per dose**5.03bn**doses **COVAX** has secured, optioned, or received as donations**370.3M**doses **shipped through COVAX** to **144** countries

Deal date	Country/territory/group	Deal type	Vaccine developer
9/17/2021	India	Bilateral	Zydus Cadila
9/18/2021	Peru	Bilateral	Pfizer BioNTech
9/18/2021	Peru	Bilateral	Sinopharm (Beijing)
9/20/2021	Viet Nam	Bilateral	Center for Genetic Engineering and Biotechnology
9/21/2021	Iran (Islamic Republic of)	Bilateral	Pfizer BioNTech
9/22/2021	Viet Nam	Bilateral	Sinopharm (Beijing)
9/24/2021	Peru	Bilateral	Moderna
9/29/2021	Switzerland	Bilateral	Janssen Pharmaceuticals
10/12/2021	COVAX	Multilateral	Moderna

.....

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)



Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.

Donut charts are ordered by proportion of pledged donations shipped.

Country Category:

Top 10 Donating Countries



Data updated on October 15th 2021.

Duke | GLOBAL HEALTH
Innovation Center





.....
.....

Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 16 Oct 2021]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)



.....
.....

Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 16 Oct 2021]

:: [47.4%](#) of the world population has received at least one dose of a COVID-19 vaccine.


:: [6.64 billion doses](#) have been administered globally, and [21.41 million](#) are now administered each day.

:: Only [2.7%](#) of people in low-income countries have received at least one dose.

Share of the population fully vaccinated against COVID-19, Oct 15, 2021

Our World in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 16 October 2021, 09:20 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY


Dec 27, 2020 Oct 15, 2021

Share of the population fully vaccinated against COVID-19, Oct 15, 2021

Our World in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 16 October 2021, 09:20 (London time)


Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

Dec 27, 2020 Oct 15, 2021

Daily COVID-19 vaccine doses administered per 100 people, Oct 15, 2021

Shown is the rolling 7-day average per 100 people in the total population. For vaccines that require multiple doses, each individual dose is counted.



.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

.....

FDA

[October 15, 2021 - Coronavirus \(COVID-19\) Update: 10/15/21](#)

:: On Oct. 12, the FDA posted information about an assessment of the Emergency Use Authorization (EUA) process that the FDA's Center for Devices and Radiological Health (CDRH) implemented to help authorize COVID-19 tests during the public health emergency. The assessment was conducted by Booz Allen Hamilton, an independent, third-party contractor. This assessment focuses on how CDRH prioritized processing of EUA requests, review times, accuracy and reliability of COVID-19 tests, a comparison to prior public health emergencies and requestors' perspectives. The [web posting](#) includes Booz Allen Hamilton's Emergency Use Authorization Assessment and recommendations and CDRH's perspectives and next steps.

Vaccines and Related Biological Products Advisory Committee- FDA

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

[Vaccines and Related Biological Products Advisory Committee October 14-15, 2021 Meeting Announcement](#)

Agenda

...Under Topic 1, the committee will meet in open session to discuss the Emergency Use Authorization (EUA) of the ModernaTX Inc. COVID-19 vaccine for the administration of an additional dose, or “booster” dose, following completion of the primary series, to individuals 18 years of age and older. On October 15, 2021, under Topic II, the committee will meet in open session to discuss the Emergency Use Authorization (EUA) of the Janssen Biotech Inc. COVID-19 vaccine for the administration of an additional dose, or “booster” dose, to individuals 18 years of age and older.

Status

No FDA decisions on VRBPAC recommendations have been posted. See J&J and Moderna announcements above.

Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Announcement - 10/26/2021 - 10/26/2021

Agenda

...The committee will meet in open session to discuss Pfizer Inc.’s request to amend its Emergency Use Authorization (EUA) to allow for the use of the Pfizer-BioNTech COVID-19 vaccine in children 5 through 11 years of age.

.....

CDC-ACIP

Next ACIP Meetings

:: October 20-21, 2021 - [Draft Agenda – October 20-21, 2021](#)

Draft agenda includes discussion and votes on pneumococcal vaccines and zoster vaccines; influenza vaccines; (COVID-19) vaccines

:: November 2-3, 2021 - No agenda posted at 16 Oct 2021

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

Remarks by President Biden on the COVID-19 Response and Vaccination Program

October 14, 2021 • Speeches and Remarks

Statement by National Security Advisor Jake Sullivan on the Global Health Security Agenda Annual Report

October 14, 2021 • Statements and Releases

Today, we are releasing the annual report, “Strengthening Health Security Across the Globe: Progress and Impact of United States Government Investments in the Global Health Security Agenda,” which details our progress and impact helping countries build health security capacity through the Global Health Security Agenda (GHSA) in fiscal year 2020. We are bringing a whole-of-government effort to address global health as a national security imperative, and this report describes how GHSA investments have been critical in advancing the COVID-19 response, and outlines our strategic approach for assisting countries to meet specific targets...

- [Strengthening Health Security Across the Globe: Progress and Impact of United States Government Investments in the Global Health Security Agenda](#)

Global Health Security Agenda - 2020 Annual Report :: 34 pages

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

October 13, 2021 • Press Briefings

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases •

[News: Meeting highlights from the Committee for Medicinal Products for Human Use \(CHMP\) 11-14 October 2021 \(new\)](#)

CHMP, Last updated: 15/10/2021

[News: EMA starts rolling review of Evusheld \(tixagevimab and cilgavimab\) \(new\)](#)

CHMP, Last updated: 14/10/2021

[News: EMA ends rolling review of CVnCoV COVID-19 vaccine following withdrawal by CureVac AG \(new\)](#)

Last updated: 12/10/2021

[News: EMA receives application for marketing authorisation for Ronapreve \(casirivimab / imdevimab\) for treatment and prevention of COVID-19 \(new\)](#)

CHMP, PDCO, PRAC, Last updated: 11/10/2021

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

News

[ECDC supports Member States to increase COVID-19 vaccination acceptance and uptake in the EU/EEA](#)

News story - 15 Oct 2021

Publication

[Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA](#)

Technical report - 15 Oct 2021

.....



European Centre for Disease Prevention and Control

COVID-19 Vaccine Tracker

Cumulative uptake of at least one dose among adults (18+) in EU/EEA	Cumulative uptake of full vaccination among adults (18+) in EU/EEA
79.4%	74.1%

Accessed 16 Oct 2021

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Press release 12 October 2021

Afghanistan: Commission announces €1 billion Afghan support package

During the G20 meeting on Afghanistan, President of the European Commission, Ursula von der Leyen, will announce a support package worth around €1 billion for the Afghan people and neighbouring countries, addressing the urgent needs in the country and the region.

Press release 11 October 2021

EU announces vital €92 million contribution in support of UNRWA's operations

The European Union has disbursed an essential payment of €92 million to the United Nations Relief and Works Agency for Palestine Refugees (UNRWA).

Questions and answers 11 October 2021

Questions and Answers: Proposal to amend EU Budget for 2021 to support global vaccination and funding for global emergencies.

... What is Draft Amending Budget 6 about?

Draft Amending Budget 6 is about providing additional support to policy areas, which need reinforcement in view of recent developments and additional needs.

More concretely, with the additional funds that Draft Amending Budget 6 will provide, the EU will be able to help speed up global vaccinations, ensure funding for global emergencies like repatriation flights from Afghanistan, reinforce the EU response to the disasters in Haiti and outstanding operations including fighting forest fires and address other pending issues.

Why is the Commission proposing to reinforce the Neighbourhood, Development and International Cooperation Instrument?

With less than 1% of global doses of vaccine for COVID-19 having been administered in low and lower-middle income countries, there is a clear and pressing need to speed up global vaccinations. The EU has already committed to share 250 million doses and stands ready to provide an additional 200 million doses to low and middle income countries through COVAX, at the latest by mid-2022. To secure these extra doses, a total of €1.3 billion will be needed. Of this total amount, €850 million are already available within existing EU budget instruments. The Draft Amending Budget 6 will provide the additional €450 million that are still needed to reach the full €1.3 billion. This is possible by mobilising the EU Flexibility Instrument, which is specifically designed to provide funding for new or unforeseen policy developments...

.....

.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment




Africa CDC Vaccine Dashboard

Africa Vaccinated

Vaccine Administered (Total)	(80.52% of supply)
Vaccine Administered (1 Dose)	(7.43% of population)
Vaccination Completed	(4.96% of population)

Total of Supply Administered



Accesses 16 Oct 2021. Full scale, interactive dashboard available at:
<https://africacdc.org/covid-19-vaccination/>

Six in seven COVID-19 infections go undetected in Africa

Brazzaville, 14 October 2021 – A new assessment by the World Health Organization (WHO) shows that only 14.2% – or one in seven – COVID-19 infections are being detected in Africa. To reverse that trend and curb transmission, the WHO Regional Office for Africa today announced a new initiative to enhance community screening for COVID-19 in eight countries. The programme aims to reach more than 7 million people with rapid diagnostic tests in the next year...

.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[Fortune - Russia has big plans for the Sputnik vaccine, and big warnings for 'the Big Pharma lobby': cut out the attacks](#)

Press release, 15.10.2021

[Interim results of a pioneering combination study in Argentina with more than 1,000 participants confirm the one-shot Sputnik Light vaccine \(the first component of the Sputnik V vaccine\) is an effective universal booster for vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino inducing strong immune response and showing high safety profile. Combination of AstraZeneca and Sputnik Light vaccines showed high immunogenicity results](#)

Press release, 14.10.2021

[One-shot Sputnik Light vaccine \(first component of the Sputnik V vaccine\) demonstrates 70% efficacy against infection with the Delta variant during the first three months after vaccination, Gamaleya Center analysis shows](#)

Press release, 13.10.2021

[Sputnik V team statement on fake news in UK media](#)

Press release, 11.10.2021

.....
.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
16 October 2021, 08:00
IST (GMT+5:30)

(↑↓ Status change since
yesterday)

Active (0.59%)

201632 (2046↓)

Discharged (98.08%)

33399961 (17861↑)

Deaths (1.33%)

451980 (166↑)

COVID-19 Vaccination
as on : 16 October
2021, 08:00 IST
(GMT+5:30)

Total Vaccination : 97,23,77,045 (8,36,118↑)

Government of India – Press Information Bureau

[Latest Press Releases](#)

[COVID-19 Vaccination Update - Day 274](#)

:: India's cumulative vaccination coverage crosses 97.62 crore

:: More than 38 lakh Vaccine doses administered today till 7 pm

Posted On: 16 OCT 2021 9:29PM by PIB Delhi

India's COVID-19 vaccination coverage has crossed 97.62 Crore(97,62,92,346) today. More than 38 lakh (38,27,173) Vaccine Doses have been administered till 7 pm today. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

See China CDC below for additional announcements.

.....
.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

<https://polioeradication.org/polio-today/polio-now/this-week/>

Polio this week as of 13 October 2021

:: In Ukraine, one case of polio caused by circulating vaccine-derived poliovirus type 2 (cVDPV2), has been confirmed. A cVDPV2 was isolated from a 17-month old girl with acute flaccid paralysis, from Rivne province (in the north-west of the country), and from six healthy contacts (siblings of the girl).
Read more...

:: Following careful review of safety and genetic stability data from mass immunization campaigns conducted with the novel oral polio vaccine type 2 (nOPV2), the Strategic Advisory Group of Experts on immunization (SAGE) endorsed the transition to the next use phase for the vaccine. Read more...

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- :: Côte d'Ivoire: one cVDPV2 case
- :: Nigeria: 18 cVDPV2 cases
- Tajikistan: four cVDPV2 positive environmental samples
- Ukraine: one cVDPV2 case

.....
.....

WHO/OCHA Emergencies

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

Afghanistan crisis *[Last apparent update: 22 September 2021]*

[Crisis in Northern Ethiopia](#) *[Last apparent update: 5 Aug 2021]*

[Ebola outbreak, Democratic Republic of the Congo, 2021](#) *[Last apparent update: 17 Aug 2021]*

[Ebola outbreak outbreak, N'Zerekore, Guinea, 2021](#) *[Last apparent update: 17 Aug 2021]*

[Coronavirus disease \(COVID-19\) pandemic](#) *[See COVID above]*

[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020](#)

[Last apparent update: 17 Aug 2021]

[Ebola outbreak, Democratic Republic of the Congo, 2018](#) *[Last apparent update: 24 July 2018]*

[Yemen crisis](#) *[Last apparent update: 12 February 2021]*

[Syria crisis](#) *[Last apparent update: 18 June 2021]*

[Somalia crisis](#) *[Last apparent update: 24 March 2018]*

[Nigeria crisis](#)

:: Case study: Pilot implementation in Nigeria and Zambia, SBI COVID-19 data collection tool

1 October 2021

[Ebola outbreak, Democratic Republic of the Congo, 2017](#) *[Last apparent update: 17 Aug 2021]*

[Zika virus disease outbreak, 2015-2016](#) *[Last apparent update: 24 Jan 2020]*

[Ebola outbreak: West Africa, 2014-2016](#) *[Last apparent update: 17 Aug 2021]*

[Iraq crisis](#) *[Last apparent update: 9 Jan 2008]*

[South Sudan crisis](#) *[Last apparent update: 23 Sep 2020]*

[Avian influenza A \(H7N9\) virus outbreak](#) *[Last apparent update: 13 September 2021]*

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) *[Last apparent update: 8 July 2019]*

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) *[Last apparent update: 10 Aug 2010]*

.....

[UN OCHA – Current Emergencies](#)

Current Corporate Emergencies

Afghanistan

[Afghanistan: Weekly Humanitarian Update \(4 – 10 October 2021\)](#)

Northern Ethiopia

[Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 14 Oct 2021](#)

HIGHLIGHTS

- Some 211 trucks of humanitarian supplies arrived in Tigray last week, up from 80 trucks a week before. Although an improvement, this is still insufficient to meet the needs.
- More than 145,000 people received food aid in Tigray (30 September-6 October). Some 870,000 people need to be reached per week to serve 5.2 million people in a six-week cycle.
- Partners also reached almost 640,000 people with food aid in Amhara Region since early August, and about 72,000 internally displaced people in Afar Region.
- **Vaccines and logistical support, including fuel, are required to vaccinate more than 887,000 children for polio and more than 790,000 children for measles to avoid outbreaks.**
- Many humanitarian partners in Tigray significantly reduced and/or halted response programs due to lack of fuel, cash and supplies.

.....

.....

WHO & Regional Offices [to 16 Oct 2021]

<https://www.who.int/>

15 October 2021

Departmental news

[Webinar: Policies to develop, attract, recruit and retain health workers in rural and remote areas, and promote gender equality for rural women through health workforce policies](#)

15 October 2021

Departmental news

[Investing \\$1 per person per year in hand hygiene could save hundreds of thousands of lives](#)

14 October 2021

News release

[Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic](#)

[See Milestones above for detail]

13 October 2021

News release

[WHO Director-General Bestows Posthumous Award on the Late Henrietta Lacks](#)

13 October 2021

News release

[WHO Announces Proposed Members of its Scientific Advisory Group for the Origins of Novel Pathogens \(SAGO\)](#)

[See Milestones above for detail]

11 October 2021

News release

[WHO's 10 calls for climate action to assure sustained recovery from COVID-19](#)

11 October 2021

Departmental news

[International Day of the Girl Child](#)

11 October 2021

Departmental news

[New stress management course for people living with adversity](#)

10 October 2021

Departmental news

[SAGE October 2021 meeting highlights](#)

[See Milestones above for detail]

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: [Six in seven COVID-19 infections go undetected in Africa](#)

Brazzaville, 14 October 2021 – A new assessment by the World Health Organization (WHO) shows that only 14.2% – or one in seven – COVID-19 infections are being detected in Africa. To reverse that trend and curb transmission, the WHO Regional Office for Africa today announced a new initiative to enhance community screening for COVID-19 in eight countries. The programme aims to reach more than 7 million people with rapid diagnostic tests in the next year...

:: [Democratic Republic of the Congo starts Ebola vaccination](#) 13 October 2021

:: [Uganda's community initiative helping HIV patients overcome depression](#) 10 October 2021

:: [Access to mental health and psychosocial support services remains unequal for children and adolescents in Africa, alert UNICEF & WHO](#) 10 October 2021

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

:: [Health and Education Ministers, heads of partner agencies commit to health promoting schools for all in WHO South-East Asia Region](#) 12 October 2021

WHO European Region EURO

:: [One case of polio detected in Ukraine](#) 13-10-2021

:: [WHO/Europe launches Western Balkans Digital Health Network](#) 13-10-2021

:: [Moldovan pharmacies contribute to pandemic response as a reliable source of information on COVID-19 vaccination](#) 12-10-2021

:: [WHO Regional Director for Europe visits Turkmenistan](#) 12-10-2021

:: [Protecting the mental health of health workers: hope and resilience in Kazakhstan](#) 11-10-2021

WHO Eastern Mediterranean Region EMRO

No new digest content identified

WHO Western Pacific Region

No new digest content identified

.....

New WHO Publications [Selected]

<https://www.who.int/publications/i>

Selected Titles

15 October 2021

[State of the world's hand hygiene](#)

15 October 2021

[WHO Drug Information - Volume 35, No. 3](#)

14 October 2021

[Global tuberculosis report 2021](#)

13 October 2021

[Fair Play: Building a strong physical activity system for more active people](#)

13 October 2021

[WHO Costing and Budgeting Tool for National Action Plans on Antimicrobial Resistance](#)

11 October 2021

[COP26 Special Report on Climate Change and Health](#)

.....

.....

CDC/ACIP [U.S.] [to 16 Oct 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements

Next ACIP Meetings

No registration is required to watch the webcast.

:: October 20-21, 2021 - [Draft Agenda – October 20-21, 2021](#)

:: November 2-3, 2021 - No agenda posted at 16 Oct 2021

MMWR News Synopsis Friday, October 15, 2021

Selected Content

**Vaccination Coverage by Age 24 Months Among Children Born in 2017 and 2018 —
National Immunization Survey-Child, United States, 2018–2020**

New CDC data show that prior to the COVID-19 pandemic, most parents in the U.S. continued to protect their children by following CDC's Advisory Committee on Immunization Practices (ACIP) recommended vaccine schedule. However, there are disparities in vaccination coverage based on health insurance status, race/ethnicity, poverty level, and jurisdiction. Despite challenges caused by the COVID-19 pandemic, it is important to remain vigilant to ensure that children get the vaccines they need and catch up on any missed doses to protect them against serious and sometimes deadly diseases.

While routine vaccination among children remains high, parents and providers should use any clinician visit as an opportunity for the child to get recommended vaccinations that are due or might have been missed because of COVID-related disruptions. According to the latest National Immunization Survey-Child (NIS-Child), during 2018-2020, over 90% of children were fully vaccinated against measles, mumps, and rubella (MMR), polio, hepatitis B, and varicella by age 24 months. While CDC's Vaccines for Children (VFC) Program helps provide vaccines to children whose families may not be able to afford them, the study found that barriers to health care access associated with health insurance status and poverty level may keep some parents from getting their children vaccinated.

Coronavirus Disease 2019 (COVID-19)- CDC

Approximately 25 announcements/reports/data summaries.

.....
.....

Africa CDC [to 16 Oct 2021]

<http://www.africacdc.org/>

News

The Government of Democratic Republic of Congo Reported an Outbreak of Ebola Virus Disease in Beni Health Zone, North Kivu province

ADDIS ABABA, ETHIOPIA, 9 October 2021: On 8 October 2021, the Democratic Republic of Congo (DRC) Ministry of Public Health, Hygiene, and Prevention (MoH) reported a confirmed death of Ebola virus disease (EVD) in the Beni health zone, North Kivu province. This comes barely five months after the end of the most recent outbreak that was detected in the same province.

The index case is a 3-year-old male, child who died on 6 October in a local health facility after presenting with haemorrhagic symptoms. Samples collected, tested positive for Ebola virus at the Goma reference laboratory.

"We see this with great concern as we are going to fight against multiple disease outbreaks in DRC, including, cholera, monkeypox, yellow fever, meningitis and EVD, on top of the ongoing COVID-19 pandemic" said Dr John Nkengasong, the Director of Africa CDC...

.....
.....

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 16 Oct 2021]

<http://en.nhc.gov.cn/>

News

Oct 16: Daily briefing on novel coronavirus cases in China

On Oct 15, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 14 new cases of confirmed infections.

[Chinese vice-premier stresses COVID-19 containment in fall-winter season](#)

2021-10-12

National Medical Products Administration – PRC [to 16 Oct 2021]

<http://english.nmpa.gov.cn/news.html>

News

[Over 2.225b COVID-19 vaccine doses administered on Chinese mainland](#)

2021-10-15

More than 2.225 billion doses of COVID-19 vaccine had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Oct 14.

CCDC Weekly - [Weekly Reports: Current Volume \(3\)](#)

2021-10-15 / No. 42

[View PDF of this issue](#)

:: [Preplanned Studies: Assessing Impacting Factors of Dog Owners' Adoption of Dog Vaccination Against Rabies: A Cross-sectional Survey in Rural Areas — Guangxi Zhuang Autonomous Region, China, 2021](#)

:: [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, August, 2021](#)

.....
.....
.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 16 Oct 2021]

<https://alleninstitute.org/what-we-do/frontiers-group/new-s-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 16 Oct 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

No new digest content identified.

BMGF - Gates Foundation [to 16 Oct 2021]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 16 Oct 2021]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

No new digest content identified.

CARB-X [to 16 Oct 2021]

<https://carb-x.org/>

News

10.12.2021 |

[CARB-X 2020-21 Annual Report: CARB-X surpasses all goals in first five years in combatting antibiotic resistant-bacteria](#)

CARB-X closed its fifth fiscal year on July 31, 2021 with US\$361 million awarded to 92 projects funding since inception. In its latest fiscal year, CARB-X invested in 25 new projects across all three pillars – preventatives, diagnostics, and therapeutics. This year saw two more successful graduations from the portfolio, four more First-in Human programs launch, and several strategic augmentations of the portfolio including in the areas of: gonorrhea, bacteriophage, vaccines, peptides and polymyxins, and anti-virulence factors.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 16 Oct 2021]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: **[NEW] *Informed Consent: A Monthly Review – October 2021*** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 16 Oct 2021]

<http://cepi.net/>

Latest News

[Could chicken eggs help end the COVID-19 pandemic?](#)

CEPI is supporting PATH's work as part of an international consortium developing a new egg-based vaccine to tackle COVID-19, inspired by influenza vaccines in longtime use.

11 Oct 2021

[CEPI opens Call to evaluate fractional COVID-19 booster and third shots as part of efforts to stretch global vaccine supply](#)

CEPI will make up to US \$25m funding available as part of the Call, with the intention to fund several clinical trials looking at dose-sparing booster shots for different COVID-19 vaccine candidates.

11 Oct 2021

DARPA – Defense Advanced Research Projects Agency [to 16 Oct 2021]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 16 Oct 2021]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 16 Oct 2021]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

12 October 2021

[First EDCTP and Africa CDC-supported Epidemiologists and Biostatisticians start their training](#)

Emory Vaccine Center [to 16 Oct 2021]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 16 Oct 2021]

<http://www.euvaccine.eu/>

Latest News

No new digest content identified.

Fondation Merieux [to 16 Oct 2021]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 16 Oct 2021]

<https://www.gavi.org/>

News releases

11 October 2021

Vigne des Nations: 2020 vintage awarded to Gavi by Geneva Canton, for its action for global health

... This recognition honours the commitment of this organisation to guaranteeing fair and equitable access to vaccines around the world...

11 October 2021

First Swiss-donated doses ship to Sierra Leone, as part of 4 million dose pledge

GHIT Fund [to 16 Oct 2021]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.*

Global Fund [to 16 Oct 2021]

<https://www.theglobalfund.org/en/news/>

News & Stories

News

Drug-resistant TB: Business as usual no longer an option

14 October 2021 by Dr. Mohammed Yassin, Global Fund Senior Tuberculosis Advisor

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 16 Oct 2021]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 16 Oct 2021]

<http://www.hillemanlabs.org/>

Website reports "under maintenance" at inquiry

Human Vaccines Project [to 16 Oct 2021]

<http://www.humanvaccinesproject.org/>

News

HVP COVID Report

Oct 15, 2021

Kristen Jill Abboud: Should We Get Back to Worrying About the Flu?

IAVI [to 16 Oct 2021]

<https://www.iavi.org/newsroom>

Latest News

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 16 Oct 2021]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

[Ahead of COP26, Red Cross Red Crescent Movement's five asks to world leaders: "It is not too late to act: the survival of humanity depends on the actions we take today"](#)

14/10/2021

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 16 Oct 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

14/10/2021

[Ahead of COP26, Red Cross Red Crescent Movement's five asks to world leaders: "It is not too late to act: the survival of humanity depends on the actions we take today"](#)

14/10/2021

[Palau and Cook Islands lead the world on COVID-19 vaccinations](#)

Kuala Lumpur/Suva, 14 October 2021 – The small Pacific country of Palau has more than 99 per cent of its eligible population fully vaccinated, contesting top spot in the world for COVID-19 vaccination rates, according to government data.

Other Pacific nations have also raced up the global vaccine leader board. The Cook Islands has 96 per cent of the eligible population fully vaccinated while 96 per cent have received their first jab in Fiji, according to Cook Islands and Fiji Government data...

Institut Pasteur [to 16 Oct 2021]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

IOM / International Organization for Migration [to 16 Oct 2021]

<http://www.iom.int/press-room/press-releases>

News - Selected

News 15 Oct 2021

Free Movement of People a Top Priority, Say West African Nations

News 12 Oct 2021

Global Migration Under Spotlight at EU-IOM Strategic Cooperation Meeting

ISC / International Science Council [to 16 Oct 2021]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

News Press

Sir Peter Gluckman, paediatrician, biomedical scientist and science-policy expert becomes President of the International Science Council

14.10.2021

News Press

New Governing Board elected to provide scientific and strategic leadership to the International Science Council

14.10.2021

... "The new Board takes on leadership of the ISC at a critical time and I am honoured and privileged to be given the responsibility of chairing the Board," said [Peter Gluckman](#), incoming President of the ISC. Membership of the Governing Board reflects the multi-disciplinarity of the Council's membership base, as well as regional and gender diversity.

The new Governing Board faces the ongoing challenge of ensuring that science has an increasing impact on the multilateral agenda. The natural and social sciences have a critical role to play as the world faces complex challenges from COVID-19 to climate change, and from conflict reduction to inequality, health inequalities, poverty, food, water and energy challenges, and coexistence with rapidly advancing technologies. These issues are compounded by disinformation and the politicisation of knowledge. At the same time, the nature and conduct of science is changing rapidly and the ISC has a critical role to play in working with the scientific community, the policy community and society to ensure better outcomes for people and the planet.

Amongst its duties, the Governing Board provides strategic leadership and develops priority activity and business plans for approval by the General Assembly, as well as monitoring the implementation and performance of such plans. The Board oversees the scientific activities and other operations of the Council and reports to the General Assembly, as well as proposing budgetary outlines and the scale of annual dues to be paid by Members...

News Press

Ten outstanding individual scientists and organizations celebrated in first ever ISC Awards

13.10.2021

IVAC [to 16 Oct 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 16 Oct 2021]

<http://www.ivi.int/>

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [to 16 Oct 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

No new digest content identified.

MSF/Médecins Sans Frontières [to 16 Oct 2021]

<http://www.msf.org/>

Latest [Selected Announcements]

Haiti

[Two months after the earthquake, health needs remain high](#)

Project Update 15 Oct 2021

Lebanon

[Breaking barriers to mental health care in Lebanon](#)

Project Update 14 Oct 2021

Syria

[Worst wave yet of COVID-19 in northern Syria overwhelms health system](#)

Press Release 13 Oct 2021

Mental health

[Mental health care needs enormous around the world](#)

Project Update 10 Oct 2021

National Academy of Medicine - USA [to 16 Oct 2021]

<https://nam.edu/programs/>

Selected News/Programs/Events

Oct 2021

[Crossing the Policy and Equity Chasm: Lessons from Compounding Health Crises \(NAM Annual Meeting 2021\)](#)

Time: 8:00 AM

The National Academy of Medicine will hold its annual meeting on Sunday and Monday, October 17-18, 2021. Due to the ongoing COVID-19 pandemic and in an abundance of caution, the Annual Meeting will be held entirely virtually. In order to help support this event, the symposium will cost \$50 to attend live on October 17 and 18.

National Academy of Sciences - USA [to 16 Oct 2021]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 16 Oct 2021]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 16 Oct 2021]

<http://www.nih.gov/news-events/news-releases>

News Releases

Antibody treatment for MIS-C works by depleting inflammatory immune cells

October 15, 2021 — NIH-funded study explains how intravenous immune globulin helps children with rare COVID condition.

NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests

October 14, 2021 — The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.

New, highly innovative NIH research awards to address health disparities and advance health equity

October 13, 2021 — Eleven grants were awarded to support the work of exceptionally creative researchers across the United States through the NIH Common Fund's Transformative Research to Address Health Disparities and Advance Health Equity initiative.

PATH [to 16 Oct 2021]

<https://www.path.org/media-center/>

Press Releases

Real-world performance of nOPV2 reinforces strong safety profile

October 11, 2021 by PATH

Experts endorse successful completion of initial use period

The Strategic Advisory Group of Experts on Immunization (SAGE) – an independent group of scientific experts that advises the World Health Organization (WHO) on vaccines and immunization – has endorsed the strong safety performance of nOPV2 use in real-world settings. SAGE reviewed data from the initial use period for nOPV2, which began in November 2020.

Since 2015, PATH has helped advance the development of nOPV2 by serving as the convener of the product development consortium; providing technical input into manufacturing and clinical trials; overseeing the development and execution of novel tests to assess the vaccine's genetic stability; and facilitating data-sharing among partners.

In November 2020, the vaccine received a recommendation for initial use under WHO's Emergency Use Listing (EUL) procedure, based on the urgent need to contain outbreaks and on promising clinical data from Phase 1 and Phase 2 nOPV2 trials....

Fact sheet

Sabin Vaccine Institute [to 16 Oct 2021]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 16 Oct 2021]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

13 October 2021

[Community mobilization and digital technologies accelerate the response to HIV and COVID-19 in Gabon](#)

12 October 2021

[Partnering to strengthen community engagement in the HIV and COVID-19 responses in Namibia](#)

11 October 2021

[Helping Haiti build a sustainable HIV response](#)

11 October 2021

[People living with HIV at higher risk of COVID-19 illness but have lower access to COVID-19 vaccines](#)

UNHCR Office of the United Nations High Commissioner for Refugees [to 16 Oct 2021]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

[World Food Day: Celebrating efforts to strengthen local food systems for displaced and host communities](#)

13 Oct 2021

UNICEF [to 16 Oct 2021]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Press release

10/15/2021

[UNICEF: 75 years of engagement in and with Europe, but no time to celebrate!](#)

"Bold and effective commitment to children's rights are important more than ever before in the EU, and with the EU for the world", says UNICEF's Deputy Executive Director, Charlotte Petri Gornitza

Press release

10/15/2021

[FACT SHEET: On Global Handwashing Day, UNICEF warns that 3 in 10 people do not have basic handwashing facilities at home to fight off infectious diseases](#)

Unitaid [to 16 Oct 2021]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 16 Oct 2021]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 16 Oct 2021]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 16 Oct 2021]

<http://www.vaccineconfidence.org/>

News, Research and Reports

[Coronavirus global impact](#)

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Vaccine Education Center – Children’s Hospital of Philadelphia [to 16 Oct 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 16 Oct 2021]

<https://wellcome.ac.uk/news>

News and reports

No new digest content identified.

The Wistar Institute [to 16 Oct 2021]

<https://www.wistar.org/news/press-releases>

Press Releases

Press Release

Oct. 14, 2021

[Dr. Anthony Fauci and Philadelphia FIGHT’s Jane Shull Receive Wistar Legacy Award at 25th Anniversary of Jonathan Lax Memorial Lecture](#)

Virtual event celebrates local HIV research and advocacy influencers/communities that paved way for global HIV impact

WFPHA: World Federation of Public Health Associations [to 16 Oct 2021]

<https://www.wfpha.org/>

Latest News

Reducing Maternal Mortality Ratio in low- and Middle Income Countries

Oct 14, 2021

Reducing Maternal Mortality Ratio in low- and Middle-income CountriesThe World Health Organization (WHO) has long identified maternal mortality as a global priority for improving global health outcomes. Yet, the United Nations Millennium...

Policy Statement on Climate Change

Oct 14, 2021

Policy Statement on Climate ChangeClimate change is a global problem. It is harming human health and wellbeing today, and we have clear evidence that lack of effective response will render the global poor, people living in low lying areas, along...

Polio Eradication: Last Battle?

Oct 12, 2021

Polio Eradication: Last Battle?Poliomyelitis (polio) is a highly infectious viral disease that attacks the nervous system and can cause irreversible paralysis and death. There is no cure for polio, it can only be prevented through immunisation....

World Bank [to 16 Oct 2021]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

Accelerating COVID-19 Vaccine Uptake to Boost Malawi's Economic Recovery

Since the onset of the COVID-19 pandemic, many countries including Malawi have struggled to mitigate its impact amid limited fiscal support and fragile health systems. The pandemic has plunged the continent...

Date: October 13, 2021 Type: Opinion

Improving Maternal and Children Health Care in Times of Cholera

Challenge Ten months after a devastating earthquake hit in 2010, a severe cholera outbreak placed additional pressure on Haiti's already fragile health system, further compromising the welfare and health...

Date: October 13, 2021 Type: Result Brief

Low-Income Country Debt Rises to Record \$860 Billion in 2020

Debt reduction, restructuring, and transparency needed to help low-income countries overcome debt challenges

WASHINGTON, Oct. 11, 2021— Governments around the world responded to the COVID-19 pandemic with massive fiscal, monetary, and financial stimulus packages. While these measures were aimed at addressing the health emergency, cushioning the impact of the pandemic on the poor and

vulnerable and putting countries on a path to recovery, the resulting debt burden of the world's low-income countries rose 12% to a record \$860 billion in 2020, according to a new World Bank report.

Even prior to the pandemic, many low- and middle-income countries were in a vulnerable position, with slowing economic growth and public and external debt at elevated levels. External debt stocks of low- and middle-income countries combined rose 5.3% in 2020 to \$8.7 trillion. According to the new International Debt Statistics 2022 report, an encompassing approach to managing debt is needed to help low- and middle-income countries assess and curtail risks and achieve sustainable debt levels.

"We need a comprehensive approach to the debt problem, including debt reduction, swifter restructuring and improved transparency," said World Bank Group President David Malpass.

"Sustainable debt levels are vital for economic recovery and poverty reduction."

The deterioration in debt indicators was widespread and impacted countries in all regions. Across all low- and middle-income countries, the rise in external indebtedness outpaced Gross National Income (GNI) and export growth. Low- and middle-income countries' external debt-to-GNI ratio (excluding China) rose to 42% in 2020 from 37% in 2019 while their debt-to-export ratio increased to 154% in 2020 from 126% in 2019...

World Customs Organization – WCO [to 16 Oct 2021]

<http://www.wcoomd.org/>

Latest News – Selected Items

13 October 2021

[WCO concludes the cycle of regional consultations on the Strategic Plan with the Asia/Pacific region](#)

World Organisation for Animal Health (OIE) [to 16 Oct 2021]

<https://www.oie.int/en/media/news/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 16 Oct 2021]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

[Members pursue convergence for an IP COVID-19 response](#)

14 October 2021

At a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 13-14 October 2021, WTO members noted encouraging exchanges at recent small group discussions and bilateral meetings which helped to identify points of convergence on how to provide a common intellectual property (IP) response to COVID-19. The chair of the TRIPS Council, Ambassador Dagfinn Sørli of Norway, announced he would continue to consult with members on how to move towards a consensus before the WTO's 12th Ministerial Conference (MC12), to be held on 30 November — 3 December

News item

[See COVID above for detail]

[WTO briefs members and observers on COVID-19 related initiatives and analysis](#)

12 October 2021

Over 180 representatives from 111 members and observers participated on 12 October in a virtual information session on the WTO Secretariat's work to support equitable access to COVID-19 vaccines. Deputy Director-General Anabel González hosted the Virtual Information Session on Access to COVID-19 Vaccines, Collaborative Initiatives and Analysis on Supply Chains and Tariffs. She briefed participants on the Secretariat's contributions to a range of collaborative initiatives, such as the Multilateral Leaders Task Force on COVID-19, the WHO, WIPO, WTO Trilateral Cooperation in support of capacity building, the COVAX Manufacturing Task Force and the Access to COVID-19 Tools (ACT) Accelerator.

The programme included presentations on the most recent information notes prepared by the WTO Secretariat:

:: update of the Indicative List of Trade-Related Bottlenecks and Trade-Facilitating Measures on Critical Products to Combat COVID-19, a Joint Indicative List of Critical COVID-19 Vaccine Inputs,

:: new report on COVID-19 vaccines production and tariffs on vaccine inputs,

:: comments by the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO).

The recording of the session is available here. The programme and background materials are available here. The WTO COVID-19 gateway is available here.

News item

.....

ARM [Alliance for Regenerative Medicine] [to 16 Oct 2021]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 16 Oct 2021]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 16 Oct 2021]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 16 Oct 2021]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 16 Oct 2021]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

R&D-based pharmaceutical industry's innovative partnerships to meet urgent global supply needs

05 October 2021

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

International Alliance of Patients' Organizations – IAPO [to 16 Oct 2021]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 16 Oct 2021]

<http://www.phrma.org/>

Latest News [Selected]

New report shows more than 260 medicines in development to fight neurodegenerative diseases

October 12, 2021

Today, PhRMA released a new report detailing the more than 260 medicines in development for 29 neurodegenerative diseases.

Blog Post

*

*

*

*

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 10: E757-831

<https://journalofethics.ama-assn.org/issue/palliative-surgery>

Palliative Surgery

Palliative care is not just for dying patients. In fact, dying patients are living patients, and all patients deserve palliation. Contrary to popular belief among many patients and clinicians, palliative interventions can be invasive and include not only medical, but surgical care. In any case, palliative care should be defined by intention: partnering clinicians, patients, and their loved ones aim neither to cure disease nor to prolong life, but to improve the quality of a patient's life at any needed time. Quality of life is motivated by goal-elucidating conversation, counseling, and symptom management-directed intervention. This issue investigates surgical palliation specifically, with sharp focus on intention formation and trust preservation.

American Journal of Infection Control

October 2021 Volume 49 Issue 10 p1215-1342

<http://www.ajicjournal.org/current>

Major Articles

[Introduction of the BNT162b2 vaccine during a COVID-19 nursing home outbreak](#)

M. Catherine McEllistrem, et al.

Published online: August 04, 2021

p1237-1241

State of the Science Review

[Intention to COVID-19 vaccination and associated factors among health care workers: A systematic review and meta-analysis of cross-sectional studies](#)

Chuxuan Luo, et al.

Published online: July 14, 2021

p1295-1304

American Journal of Preventive Medicine

September 2021 Volume 61 Issue 3 p311-464

<https://www.ajpmonline.org/current>

Research Articles

[Racial/Ethnic and Socioeconomic Disparities in Adult Vaccination Coverage](#)

Kosuke Kawai, Alison Tse Kawai

Published online: July 29, 2021

p465-473

American Journal of Public Health

October 2021 111(10)

<http://ajph.aphapublications.org/toc/ajph/current>

EDITORIALS

[Public Health Responses to Pandemics in 1918 and 2020](#)

History, Epidemiology

E. Thomas Ewing

111(10), pp. 1715–1717

NOTES FROM THE FIELD

Implementation of a COVID-19 Mass Vaccination Clinic to College Students in Montana

Immunization/Vaccines, Other Race/Ethnicity, Race/Ethnicity

Sally Moyce, Julie Ruff, Ann Galloway and Sarah Shannon

111(10), pp. 1776–1779

EDITORIALS

Public Health Responses to Pandemics in 1918 and 2020

History, Epidemiology

E. Thomas Ewing

111(10), pp. 1715–1717

NOTES FROM THE FIELD

COVID-19 Case Rates After Surveillance and Vaccinations in a Statewide Psychiatric Hospital System

Immunization/Vaccines, Surveillance, Mental Health, Statistics/Evaluation/Research, Health Care Facilities/Services

Thomas E. Smith, Ian T. Rodgers, Daniel J. Silverman, Sally R. Dreslin, Mark Olfson, Lisa B. Dixon and Melanie M. Wall

111(10), pp. 1780–1783

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 2 (Aug 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/2/tpmd.105.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

September 2021 Volume 174, Issue 9

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 299 October 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/299/suppl/C>

Research article Abstract only

Levels of explainable artificial intelligence for human-aligned conversational explanations

Richard Dazeley, Peter Vamplew, Cameron Foale, Charlotte Young, ... Francisco Cruz

Article 103525

This paper aims to define levels of explanation and describe how they can be integrated to create a human-aligned conversational explanation system.

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 16 Oct 2021)

[No new digest content identified]

BMJ Global Health

September 2021 - Volume 6 - 9

<https://gh.bmj.com/content/6/9>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 16 Oct 2021)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 16 Oct 2021)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 16 Oct 2021)

[Assessment of the appropriateness of the i-CONSENT guidelines recommendations for improving understanding of the informed consent process in clinical studies](#)

The H2020 i-CONSENT project has developed a set of guidelines that offer ethical recommendations and practical tools aimed at making the informed consent process in clinical studies more comprehensive, tailored, and inclusive. An analysis of the appropriateness of some of its novel recommendations was carried out by a group of experts representing different stakeholders.

Authors: Jaime Fons-Martinez, Cristina Ferrer-Albero and Javier Diez-Domingo

Content type: Research

13 October 2021

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 16 Oct 2021)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 16 Oct 2021)

[No new digest content identified]

BMC Public Health

<http://bmcpublihealth.biomedcentral.com/articles>

(Accessed 16 Oct 2021)

Knowledge, attitudes and perceptions towards COVID-19 vaccinations: a cross-sectional community survey in Bangladesh

Several vaccines have been approved for use against coronavirus disease (COVID-19) and distributed globally in different regions. However, general community knowledge, attitudes and perceptions towards COVID-1...

Authors: Md. Saiful Islam, Abu Bakkar Siddique, Rejina Akter, Rafia Tasnim, Md. Safaet Hossain Sujan, Paul R. Ward and Md. Tajuddin Sikder

Citation: BMC Public Health 2021 21:1851

Content type: Research

Published on: 13 October 2021

Determinants of HPV-vaccination uptake and subgroups with a lower uptake in the Netherlands

In the Netherlands, the HPV-vaccine uptake was 52% during the 2009 catch-up campaign (birth cohorts 1993–1996). This increased to 61% in the regular immunization program (birth cohorts 2000–2001). However for ...

Authors: A. C. de Munter, T. M. Schurink-van t Klooster, A. van Lier, R. Akkermans, H. E. de Melker and W. L. M. Ruijs

Citation: BMC Public Health 2021 21:1848

Content type: Research

Published on: 12 October 2021

The knowledge, attitudes and beliefs of midwives on the vaccination coverage rates in Perth's Aboriginal children

Midwives are well placed to promote vaccination awareness throughout a women's pregnancy and strengthen childhood vaccination demand following hospital discharge. In Perth, Western Australia, Aboriginal childr...

Authors: Rebecca Carman, Lesley Andrew and Amanda Devine

Citation: BMC Public Health 2021 21:1845

Content type: Research

Published on: 12 October 2021

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 16 Oct 2021)

[No new digest content identified]

BMJ Evidence-Based Medicine

October 2021 - Volume 26 - 5

<https://ebm.bmj.com/content/26/5>

[Reviewed earlier]

BMJ Open

October 2021 - Volume 11 - 10

<https://bmjopen.bmj.com/content/11/10>

Articles

[Original research: A mixed methods study to develop a tool to assess institutional readiness to conduct knowledge translation activities in low-income and middle-income countries](#) (11 October, 2021)

Anna Kalbarczyk, Aditi Rao, Olakunle Alonge

This study identifies a tool for assessing readiness of LMIC academic institutions to conduct KT and unique opportunities for building capacity. The organisational focus of these factors underscores the need for strategies that address organisational systems and structures in addition to individual skills. Future research will be conducted to understand determinants of these factors and develop a comprehensive set of capacity building strategies responsive to academic institutions in LMICs.

Bulletin of the World Health Organization

Volume 99(10); 2021 Oct 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/390889/>

[Reviewed earlier]

Cell

Oct 14, 2021 Volume 184 Issue 21 p5261-5496

<https://www.cell.com/cell/current>

Commentary

[The surprise element: A hallmark of creativity in scientists, artists, and comedians](#)

Joseph L. Goldstein

Truly creative works of science and art produce unexpected and surprising results—just like the punch line of a good joke that generates an unfamiliar twist on a familiar idea. Surprise stimulates curiosity, which triggers a search to reveal the mystery of things unknown.

Benchmarks

[Delivering the message: How a novel technology enabled the rapid development of effective vaccines](#)

Lucy Shapiro, Richard Losick

This year's Lasker~DeBakey Clinical Research Award honors Katalin Karikó and Drew Weissman for the development of a therapeutic technology based on nucleoside-modification of messenger RNA, enabling the rapid development of the highly effective COVID-19 vaccines.

Child Care, Health and Development

Volume 47, Issue 5 Pages: 575-731 September 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 110, Issue 4 Pages: 827-1135 October 2021
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Review

Open Access

Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations

Emma Hughes, Erika Wallender, Ali Mohamed Ali, Prasanna Jagannathan, Radojka M. Savic

Pages: 926-940

First Published:24 March 2021

Mini-Review

Open Access

Assuring Access to Safe Medicines in Pregnancy and Breastfeeding

Janet Nooney, Shannon Thor, Corinne de Vries, John Clements, Leyla Sahin, Wei Hua, Darcie Everett, Cosimo Zaccaria, Robert Ball, Agnes Saint-Raymond, Lynne Yao, June Raine, Sandra Kweder

Pages: 941-945

First Published:21 February 2021

Free Access

Clinical Pharmacology Worldwide: A Global Health Perspective

Larissa Wenning, Goonaseelan (Colin) Pillai, Todd C. Knepper, Katarina Ilic, Ali Mohamed Ali, Jennifer E. Hibma

Pages: 946-951

First Published:24 April 2021

Tutorial

Open Access

Benefit-Risk Assessment of Off-Label Drug Use in Children: The Bravo Framework

Tjitske M. van der Zanden, Miriam G. Mooij, Nienke J. Vet, Antje Neubert, Wolfgang Rascher, Florian B. Lagler, Christoph Male, Helene Grytli, Thomas Halvorsen, Matthijs de Hoog, Saskia N. de Wildt

Pages: 952-965

First Published:18 June 2021

Clinical Therapeutics

June 2021 Volume 43 Issue 6 p917-1134

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 18 Issue 5, October 2021

<https://journals.sagepub.com/toc/ctja/18/5>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 16 Oct 2021]
[No new digest content identified]

Contemporary Clinical Trials

Volume 108 September 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/108/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 4, Issue 4 / August 2021

<https://www.liebertpub.com/toc/crispr/4/4>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 3, September 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-3>

[Reviewed earlier]

Current Opinion in Infectious Diseases

October 2021 - Volume 34 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

TROPICAL AND TRAVEL-ASSOCIATED DISEASES

Edited by Christina M. Coyle

[**Zoonoses and global epidemics**](#)

Judson, Seth D.; Rabinowitz, Peter M.

Current Opinion in Infectious Diseases. 34(5):385-392, October 2021.

[**Policy and planning for large epidemics and pandemics – challenges and lessons learned from COVID-19**](#)

Sharp, Ashley; Jain, Vageesh; Alimi, Yewande; More

Current Opinion in Infectious Diseases. 34(5):393-400, October 2021.

[**COVID-19 transmission and the safety of air travel during the pandemic: a scoping review**](#)

Khatib, Aisha N.; McGuinness, Sarah; Wilder-Smith, Annelies

Current Opinion in Infectious Diseases. 34(5):415-422, October 2021.

PAEDIATRIC AND NEONATAL INFECTIONS

[**Parental vaccine hesitancy: scope, causes, and potential responses**](#)

Cataldi, Jessica R.; O'Leary, Sean T.

Current Opinion in Infectious Diseases. 34(5):519-526, October 2021.

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>
[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 3 Pages: 97-148 September 2021
<https://onlinelibrary.wiley.com/toc/14718847/current>
[Reviewed earlier]

Development in Practice

Volume 31, Issue 7, 2021
<http://www.tandfonline.com/toc/cdip20/current>
The Private Sector in the Development Landscape.
Guest Editors: Jason Hart, Jo-Anna Russon & Jessica Sklair
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 3 - June 2021
<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>
[Reviewed earlier]

Disasters

Volume 45, Issue 4 Pages: 739-995 October 2021
<https://onlinelibrary.wiley.com/toc/14677717/current>
[Reviewed earlier]

EMBO Reports

Volume 22 Issue 9 6 September 2021
<https://www.embopress.org/toc/14693178/current>
[Reviewed earlier]

Emerging Infectious Diseases

Volume 27, Number 9—September 2021
<http://wwwnc.cdc.gov/eid/>
[Reviewed earlier]

Epidemics

Volume 36 September 2021
<https://www.sciencedirect.com/journal/epidemics/vol/36/suppl/C>
[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 5 Pages: 1-44 September–October 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

Ethics & International Affairs

Summer 2021 (35.2) August 2021

<https://www.ethicsandinternationalaffairs.org/2021/spring-2021-35-1/>

The editors of *Ethics & International Affairs* are pleased to present the Summer 2021 issue of the journal! The highlight of this issue is a roundtable organized by Adrian Gallagher on the responsibility to protect in a changing world order. The roundtable contains an introductory essay by Michael Ignatieff and contributions from Adrian Gallagher and Nicholas J. Wheeler; Cristina G. Stefan; Luke Glanville and James Pattison; and Jennifer M. Welsh. Additionally, the issue includes feature articles by Daniele Amoroso and Guglielmo Tamburrini on meaningful human control over weapons systems and Patricia Goff on inclusive trade. It also contains a review essay by Andrea C. Simonelli on climate displacement and justice and book reviews by Reed Bonadonna, Cian O'Driscoll, and Shelley Wilcox.

[Reviewed earlier]

Ethics, Medicine and Public Health

September 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/18/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

SUPPLEMENT - Volume 31, Issue Supplement_1, July 2021

https://academic.oup.com/eurpub/issue/31/Supplement_1

Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders' Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions

Mental illness represents an enormous personal, social and societal burden for European citizens¹ calling for the need to expand existing models of mental healthcare delivery. In Europe, the Internet is a key source of health information,² and technology-enhanced (psychological) interventions such as Internet- and mobile-delivered applications ('eHealth'³ and 'm-Health'⁴) have become increasingly popular and studied. There is already strong evidence of the efficacy of online interventions for the prevention and treatment of several psychological disorders^{5,6} and meta-analyses show effect sizes similar to face-to-face interventions.⁷

Expert Review of Vaccines

Vol 20 (9) 2021
<https://www.tandfonline.com/toc/ierv20/current>
[Reviewed earlier]

Forum for Development Studies

Volume 48, 2021 - Issue 2
<http://www.tandfonline.com/toc/sfds20/current>
[Reviewed earlier]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>
[Accessed 16 Oct 2021]
[No new digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>
[Accessed 16 Oct 2021]

Research

[Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases](#)

Clinical interpretation of genetic variants in the context of the patient's phenotype is becoming the largest component of cost and time expenditure for genome-based diagnosis of rare genetic diseases. Artific...

Authors: Francisco M. De La Vega, Shimul Chowdhury, Barry Moore, Erwin Frise, Jeanette McCarthy, Edgar Javier Hernandez, Terence Wong, Kiely James, Lucia Guidugli, Pankaj B. Agrawal, Casie A. Genette, Catherine A. Brownstein, Alan H. Beggs, Britt-Sabina Löscher, Andre Franke, Braden Boone...

Citation: Genome Medicine 2021 13:153

Published on: 14 October 2021

Global Health Action

Volume 14, Issue 1 (2021)
<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>
[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 3 September 30, 2021
<http://www.ghspjournal.org/content/current>
[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>
[Accessed 16 Oct 2021]

[No new digest content identified]

Global Public Health

Volume 16, Issue 10 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 16 Oct 2021]

[No new digest content identified]

Health and Human Rights

Volume 23, Issue 1, June 2021

<https://www.hhrjournal.org/volume-23-issue-1-june-2021/>

[Reviewed earlier]

Health Economics, Policy and Law

Volume 16 - Issue 4 - October 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 36, Issue 8, October 2021

<https://academic.oup.com/heapol/issue/36/8>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 16 Oct 2021]

[Governance of health research in four eastern and southern African countries](#)

Health research governance is an essential function of national health research systems. Yet many African countries have not developed strong health research governance structures and processes. This paper pre...

Authors: Pamela A. Juma, Catherine M. Jones, Rhona Mijumbi-Deve, Clare Wenham, Tiny Masupe, Joelle Sobngwi-Tambekou, Godfrey Biemba, Namuunda Mtombo and Justin Parkhurst

Citation: Health Research Policy and Systems 2021 19:132

Content type: Research

Published on: 13 October 2021

Human Gene Therapy

Volume 32, Issue 17-18 / September 2021
<https://www.liebertpub.com/toc/hum/32/17-18>
[Reviewed earlier]

Humanitarian Exchange Magazine

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

Localisation and local humanitarian action

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 10, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Immunity [NEW JOURNAL ADDED]

Oct 12, 2021 Volume 54 Issue 10 p2169-2436

<https://www.cell.com/immunity/current>

Primer

Transition to endemicity: Understanding COVID-19

Rustom Antia, M. Elizabeth Halloran

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated disease, coronavirus disease 2019 (COVID-19), has caused a devastating pandemic worldwide. Here, we explain basic concepts underlying the transition from an epidemic to an endemic state, where a pathogen is stably maintained in a population. We discuss how the number of infections and the severity of disease change in the transition from the epidemic to the endemic phase and consider the implications of this transition in the context of COVID-19.

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 16 Oct 2021]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 16 Oct 2021]

COVID-19 vaccination program in the mainland of China: a subnational descriptive analysis on target population size and current progress

Authors: Wen Zheng, Xuemei Yan, Zeyao Zhao, Juan Yang and Hongjie Yu

Content type: Research Article

15 October 2021

International Health

Volume 13, Issue 5, September 2021

<https://academic.oup.com/inthealth/issue/13/5>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 1 (Jun 2021)

<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 8, No 10 (2021) October 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/81>

Original Research Articles

Demographic and KAP determinants of COVID-19 vaccine hesitancy and vaccine refusal: a cross-sectional study in Indian population

Meghna Gupta, Rohit Goyal, Shruti Aggarwal, Mansunderbir Singh, Vitull K. Gupta, Nikita Garg

DOI: [10.18203/2394-6040.ijcmph20213664](https://doi.org/10.18203/2394-6040.ijcmph20213664)

A cross sectional study on COVID-19 vaccine acceptances and barriers to vaccination in district Jhansi

Vimal Arya, Mahendra Chowksey

DOI: [10.18203/2394-6040.ijcmph20213784](https://doi.org/10.18203/2394-6040.ijcmph20213784)

Public knowledge, attitude, practice towards acceptance of COVID-19 Vaccine: a prospective cross-sectional study in Bangalore

Nishchitha S., Sunil Kumar D., Chandan N., Arun Gopi, Narayan Murthy M. R., Anil S. Bilimale

DOI: [10.18203/2394-6040.ijcmph20213792](https://doi.org/10.18203/2394-6040.ijcmph20213792)

International Journal of Epidemiology

Volume 50, Issue 4, August 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

October 2021 Volume 111 p1-362

<https://www.ijidonline.com/current>

[Reviewed earlier]

JAMA

October 12, 2021, Vol 326, No. 14, Pages 1353-1452

<https://jamanetwork.com/journals/jama/currentissue>

Original Investigation

[Surveillance for Adverse Events After COVID-19 mRNA Vaccination](#)

Nicola P. Klein, MD, PhD; Ned Lewis, MPH; Kristin Goddard, MPH; et al.

free access has active quiz

JAMA. 2021;326(14):1390-1399. doi:10.1001/jama.2021.15072

This study reports an interim analysis of safety surveillance data of 23 serious outcomes following vaccination with 1 of the mRNA COVID-19 vaccines based on comprehensive health records from a large US population.

Editorial

[Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink](#)

Kimberly G. Blumenthal, MD, MSc; Neelam A. Phadke, MD, MPH; David W. Bates, MD, MSc

[Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021](#)

Jefferson M. Jones, MD, MPH; Mars Stone, PhD; Hasan Sulaeman, MS; et al.

free access has active quiz

JAMA. 2021;326(14):1400-1409. doi:10.1001/jama.2021.15161

This study estimates trends in SARS-CoV-2 seroprevalence related to infection and vaccination in the US population.

Editorial

[Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink](#)

Kimberly G. Blumenthal, MD, MSc; Neelam A. Phadke, MD, MPH; David W. Bates, MD, MSc

JAMA Network

[COVID-19 Update October 16, 2021](#)

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

October 2021, Vol 175, No. 10, Pages 990-1088

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Viewpoint

COVID-19 Vaccination of Minors Without Parental Consent Respecting Emerging Autonomy and Advancing Public Health

Larissa Morgan, JD, MBE; Jason L. Schwartz, PhD; Dominic A. Sisti, PhD

free access

JAMA Pediatr. 2021;175(10):995-996. doi:10.1001/jamapediatrics.2021.1855

This Viewpoint discusses allowing minors to consent and receive the COVID-19 vaccine without parental authorization.

Research Letter

Summary of Literature on Pediatric Real-world Evidence and Effectiveness

Ann W. McMahon, MD, MS; Kenneth Quinto, MD, MPH; Amy Abernethy, MD, PhD; et al.

JAMA Pediatr. 2021;175(10):1077-1079. doi:10.1001/jamapediatrics.2021.2149

This cross-sectional study investigates the use of real-world data and real-world evidence in informing medicine efficacy in pediatric literature.

JBIC Evidence Synthesis

October 2021 - Volume 19 - Issue 10

<https://journals.lww.com/jbisir/Pages/currenttoc.aspx>

EDITORIALS

Striving for evidence-based health care with eHealth and technology in a time of half-truths and disinformation

Dol, Justine; Dennis, Cindy-Lee

JBIC Evidence Synthesis. 19(10):2474-2475, October 2021.

Journal of Adolescent Health

October 2021 Volume 69 Issue 4 p533-682

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 72 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 46, issue 5, October 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-5>

[Reviewed earlier]

Journal of Development Economics

Volume 152 September 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/152/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 16 Issue 4, October 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

September 2021 - Volume 75 - 9

<https://jech.bmj.com/content/75/9>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 3 Pages: 171-256 September 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 11, Issue 1, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 3, August 2021

<https://muse.jhu.edu/issue/45771>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 23, issue 5, October 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-5>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 224, Issue 6, 15 September 2021

<https://academic.oup.com/jid/issue/224/6>

[Reviewed earlier]

Journal of Medical Ethics

October 2021 - Volume 47 - 10

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 3 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

October 2021 Volume 237 p1-324

<http://www.jpeds.com/current>

[New issue; No digest content identified]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 16 Oct 2021]

[No new digest content identified]

Journal of Public Health Management & Practice

September/October 2021 - Volume 27 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 3, September 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-3>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

October 2021 Volume 18 Issue 183

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 7, October 2021

<https://academic.oup.com/jtm/issue>

Perspectives

India's role in COVID-19 vaccine diplomacy

Khan Sharun, MVSc, Kuldeep Dhama, PhD

Journal of Travel Medicine, Volume 28, Issue 7, October 2021, taab064,

<https://doi.org/10.1093/jtm/taab064>

Indian vaccine manufacturers such as Serum Institute of India, Bharat Biotech, Dr Reddy's Laboratories, Biological E Limited, Aurobindo Pharma and Indian Immunologicals have already secured the license to manufacture major vaccine candidates. The ability of the country to manufacture cost-effective COVID-19 vaccines will help to meet the global vaccine requirements.

Review

Unintended health and societal consequences of international travel measures during the COVID-19 pandemic: a scoping review

Carmen Klinger, MSc, Jacob Burns, MSc, Ani Movsisyan, PhD, Renke Biallas, MSc, Susan L Norris, MD

...

Journal of Travel Medicine, Volume 28, Issue 7, October 2021, taab123,

<https://doi.org/10.1093/jtm/taab123>

Rapid Communications

COVID-19 in fully vaccinated Everest trekkers in Nepal

Bhawana Amatya, MD, Prativa Pandey, MD, Suvash Dawadi, MD, Shanta Manandhar, MD

Journal of Travel Medicine, Volume 28, Issue 7, October 2021, taab098,

<https://doi.org/10.1093/jtm/taab098>

COVID-19 in a fully mRNA-1273 vaccinated aspiring Everest summiteer and an Everest trekker who had two doses of ChAdOx1nCoV-19 is presented. Delta B.1.617.2 variant was sequenced in one of the cases. Travellers should be wary of starting up travel to under-vaccinated regions, particularly if they are at high risk for severe disease.

Journal of Virology

Volume 95 • Number 21 • October 2021

<http://jvi.asm.org/content/current>

Spotlight 13 October 2021

Articles of Significant Interest in This Issue

<https://doi.org/10.1128/JVI.01507-21>

Natural isolates and recombinant SARS-CoV-2 viruses rapidly adapt to heparin binding in cultured cells. Shiliaev et al. (e01357-21) report that within a few passages, the viral spike protein acquires mutations in the N-terminal domain and in P1' position of the furin cleavage site. These mutations are closely located on the protein surface, increasing positive charge in the region and the affinity of the virus to heparan sulfate. These mutations make SARS-CoV-2 mutants dramatically more infectious for the cultured cells and dominant in viral pools. Such viral mutants efficiently use glycosaminoglycans for primary attachment before the high-affinity interaction with the ACE2 receptor.

The Lancet

Oct 16, 2021 Volume 398 Number 10309 p1381-1460

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

Malaria vaccine approval: a step change for global health

The Lancet

On Oct 6, WHO announced that it will be recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine for children in sub-Saharan Africa and in other regions with moderate-to-high *Plasmodium falciparum* transmission. Malaria has ravaged people's lives for centuries; today the burden falls disproportionately on children in tropical regions. 229 million cases were recorded in 2019, and 409 000 people lost their lives, two-thirds of whom were younger than 5 years and living in sub-Saharan Africa. Broad roll-out across the region is now eminently achievable. Challenges remain, but this scientific triumph could be one of the most monumental opportunities in child health for a generation.

RTS,S is the first parasite vaccine to have obtained regulatory approval. Designed to target the sporozoite phase of the lifecycle, it blocks infection of the liver, where the parasite would otherwise mature, multiply, re-enter the bloodstream, and infect erythrocytes. The first attempts at creating a malaria vaccine began in the 1960s, and the road to victory has been difficult. Most trials ended in disappointment and many observers doubted whether a malaria vaccine would ever become a reality. The success of RTS,S is the culmination of generations of scientific ingenuity, three decades of profitless research and development by GSK, the foresight of generous funders, and close collaboration within African communities.

Pivotal phase 3 trials in 2009–14 took place in Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and Tanzania. The final results, published in *The Lancet* in 2015, showed that children in these regions receiving three doses of RTS,S plus a booster dose, between 5 and 17 months of age, would have a 29% reduced risk of severe malaria. Crucial implementation programmes in Kenya, Ghana, Malawi, Burkina Faso, and Mali, which will continue until 2023, have confirmed that, when combined with seasonal malaria chemoprevention, RTS,S can reduce death from malaria by over 70%. Compliance and acceptance are high, despite the complexity of the vaccination schedule, and implementation appears realistic, even in countries with under-resourced health-care infrastructure.

WHO's endorsement of RTS,S comes at a crucial time in malaria control. Between 2000 and 2015, widespread deployment of simple but innovative control measures turned the tide against malaria. Insecticide-treated mosquito nets, indoor spraying of homes, rapid diagnostic tests, and new treatments and prophylactics are estimated to have averted 7·6 million deaths since 2000. But progress has stagnated over the past 6 years, especially in high-burden countries. Evolving mosquito and parasite populations are escaping detection by diagnostic tests and developing resistance to

insecticides and antimalarials. Only last year, WHO warned that global targets of reducing malaria case incidence and mortality rates by at least 90% by 2030 would be missed. There is hope that the vaccine can turbocharge malaria control.

How the vaccine will fit into wider programmes of malaria control remains unclear. Understandably, there are questions over who will pay to make the vaccine available to all who need it, many of whom live in countries with fragile health systems. After a period of stalled development funding for malaria control, there is optimism that international donors will fund vaccination, as noted in a World Report. A reliance on international donors need not be the only option, however. The 2019 Lancet malaria eradication Commission noted that in addition to innovative technology, such as vaccines, domestic funding for malaria control would accelerate progress. Domestic spending on health is woefully low in the sub-Saharan region, and projections suggest that this is unlikely to improve over the next 30 years. But if countries could fund health system strengthening and overcome the barriers to ensure equitable access, they might avoid pitfalls that can come from narrow, vertical approaches to global health issues, which have a history of skewing incentives and neglecting the wider needs of population health.

A strong case for investment in health to reduce child and maternal mortality was made by the Lancet Commission on Investing in Health. For a disease that kills a child every 2 minutes, a vaccine with even a modest 30% efficacy could have a considerable effect on improving child survival. Wide availability of a malaria vaccine will mean that the prospect of ending preventable child mortality within a generation is now a step closer.

Comment

[Developing COVID-19 vaccine policy in increments](#)

Michael S Saag

Articles

[Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study](#)

Sara Y Tartof, et al.

Background

Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer–BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system.

...Interpretation

Our results provide support for high effectiveness of BNT162b2 against hospital admissions up until around 6 months after being fully vaccinated, even in the face of widespread dissemination of the delta variant. Reduction in vaccine effectiveness against SARS-CoV-2 infections over time is probably primarily due to waning immunity with time rather than the delta variant escaping vaccine protection.

The Lancet Child & Adolescent Health

Oct 2021 Volume 5 Number 10 p681-766, e39-e43

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Oct 2021 Volume 3 Number 10 e612-e683

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Oct 2021 Volume 9 Number 10 e1336-e1473

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Oct 2021 Volume 21 Number 10 p1333-1470, e302-e340

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Oct 2021 Volume 6 Number 10 e696-e779

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Oct 2021 Volume 9 Number 10 p1077-1202, e96-e103

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 25, issue 10, October 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-10>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 41 Issue 7, October 2021

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 3 Pages: 601-852 September 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 598 Issue 7880, 14 October 2021

<https://www.nature.com/nature/volumes/598/issues/7880>

Editorial | 13 October 2021

[COVID scientists in the public eye need protection from threats](#)

Researchers are facing harassment for speaking out during the pandemic. Their institutions must do more to support them.

World View | 12 October 2021

[COVID lesson: trust the public with hard truths](#)

When governments assume that people will panic, that exacerbates the pandemic.

Michael Bang Petersen

Article | 26 August 2021

[Burden and characteristics of COVID-19 in the United States during 2020](#)

Data-driven modelling including numbers of cases and population movements is used to simulate the COVID-19 pandemic in the United States in 2020, providing insights into the transmission of the disease.

Pei Sen, Teresa K. Yamana, Jeffrey Shaman

Nature Biotechnology

Volume 39 Issue 10, October 2021

<https://www.nature.com/nbt/volumes/39/issues/10>

Editorial | 23 September 2021

[The champions of drug development](#)

Our new podcast series 'Hope Lies in Dreams' highlights the importance of visionaries in shepherding drugs through the setbacks of drug development to commercial success.

Analysis | 17 May 2021

[Learning on knowledge graph dynamics provides an early warning of impactful research](#)

Biotechnology-related papers predicted to be of long-term impact are identified in a machine learning framework (DELPHI) that analyzes relationships among a range of features from the scientific literature over time.

James W. Weis, Joseph M. Jacobson

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 16 Oct 2021)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 10, October 2021

<https://www.nature.com/ng/volumes/53/issues/10>

Article | 30 September 2021

[A cross-population atlas of genetic associations for 220 human phenotypes](#)

Genome-wide analyses in BioBank Japan, UK Biobank and FinnGen identify ~5,000 new loci associated with 220 human traits. Statistical decomposition of matrices of phenome-wide summary statistics further highlights variants underpinning diseases across populations.

Saori Sakaue, Masahiro Kanai, Yukinori Okada

Nature Human Behaviour

Volume 5 Issue 9, September 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/9>

[Reviewed earlier]

Nature Medicine

Volume 27 Issue 10, October 2021

<https://www.nature.com/nm/volumes/27/issues/10>

Perspective | 12 October 2021

[Individualized therapy trials: navigating patient care, research goals and ethics](#)

In this Perspective, the authors discuss the ethical challenges of individualized therapy (also called n-of-1) trials and argue that, although customized for the patient, these constitute 'research' nonetheless.

Patrick Bodilly Kane, Merlin Bittlinger, Jonathan Kimmelman

Brief Communication | 07 September 2021

[Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy](#)

In an observational cohort of pregnant women in Israel, the BNT162b2 COVID-19 vaccine was found to have effectiveness similar to that seen in the general population.

Noa Dagan, Noam Barda, Ran D. Balicer

Nature Reviews Genetics

Volume 22 Issue 10, October 2021

<https://www.nature.com/nrg/volumes/22/issues/10>

Review Article | 23 July 2021

[Advancing the use of genome-wide association studies for drug repurposing](#)

Genome-wide association studies (GWAS) have revealed important biological insights into complex diseases. The authors review approaches that leverage GWAS to identify opportunities for repurposing existing drugs, including single-loci mapping to drug targets, transcriptome-wide association studies, gene-set association, causal inference by Mendelian randomization and polygenic scoring.

William R. Reay, Murray J. Cairns

Nature Reviews Immunology

Volume 21 Issue 10, October 2021

<https://www.nature.com/nri/volumes/21/issues/10>

Progress | 09 August 2021

[Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape](#)

This Progress article provides an update on the COVID-19 vaccine effort in the light of ongoing vaccine efficacy studies and real-world data on vaccine effectiveness, including the impact of virus variants of concern and challenges for global deployment.

John S. Tregoning, Katie E. Flight, Benjamin F. Pierce

Perspective | 13 September 2021

Immune-mediated inflammatory disease therapeutics: past, present and future

In this Perspective, McInnes and Gravalles highlight the remarkable progress made over the past 20 years in treating immune-mediated inflammatory diseases. The available therapies have progressed from broad-spectrum immune modulators to highly targeted biological and small-molecule agents as our understanding of disease mechanisms has advanced.

Iain B. McInnes, Ellen M. Gravalles

Nature Reviews Drug Discovery

Volume 20 Issue 10, October 2021

<https://www.nature.com/nrd/volumes/20/issues/10>

Comment | 27 May 2021

Envisioning an actionable research agenda to facilitate repurposing of off-patent drugs

Repurposing off-patent drugs has long been proposed as a cost-effective and efficient strategy to develop new treatments, but its potential has not been realized. Here, we highlight some of the barriers that underlie this lack of progress and discuss potential strategies to address them.

Christopher P. Austin, Bobbie Ann Mount, Christine M. Colvis

Perspective | 20 July 2021

The PROTACtable genome

Targeted protein degradation by proteolysis-targeting chimeras (PROTACs) is attracting substantial interest as a therapeutic modality that could circumvent some limitations of traditional small-molecule drugs. This article presents a systematic approach to assessing the PROTAC tractability (PROTACtability) of protein targets, which could support decision-making on whether a particular target may be amenable to modulation using a PROTAC.

Melanie Schneider, Chris J. Radoux, Andrew R. Leach

New England Journal of Medicine

October 14, 2021 Vol. 385 No. 16

<http://www.nejm.org/toc/nejm/medical-journal>

Original Articles

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

M. Bergwerk and Others

Efficacy of a Cell-Culture–Derived Quadrivalent Influenza Vaccine in Children

T. Nolan and Other

Pediatrics

Vol. 148, Issue 4 1 Oct 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 39, issue 10, October 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-10>

[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 16 Oct 2021)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 16 Oct 2021)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 16 Oct 2021)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 16 Oct 2021)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 16 Oct 2021]

Research Article

[Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers](#)

Moza Alishaq, Hanaa Nafady-Hego, Andrew Jeremijenko, Jameela Ali Al Ajmi, Mohamed Elgendy, Suni Vinoy, Sameera Bihi Fareh, Justine Veronica Plaatjies, Mariam Nooh, Nadya Alanzi, Anvar H. Kaleeckal, Ali Nizar Latif, Peter Coyle, Hamed Elgendy, Abdul-Badi Abou-Samra, Adeel Ajwad Butt

Research Article | published 15 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0258820>

[Catch-up immunization for adolescents and young adults during pre-travel consultation in Japan](#)

Kei Yamamoto, Michiyo Suzuki, Mugen Ujiie, Shuzo Kanagawa, Norio Ohmagari

Research Article | published 14 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0258357>

Knowledge, attitude and practice of influenza vaccination among Lebanese parents: A cross-sectional survey from a developing country

Ramia Zakhour, Hani Tamim, Farah Faytrouni, Joanne Khoury, Maha Makki, Lama Charafeddine

Research Article | published 14 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0258258>

Effects of COVID-19 on trade flows: Measuring their impact through government policy responses

Javier Barbero, Juan José de Lucio, Ernesto Rodríguez-Crespo

Research Article | published 13 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0258356>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 16 Oct 2021]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

October 05, 2021; vol. 118 no. 40

<https://www.pnas.org/content/118/40>

Political Sciences

Trust in scientists in times of pandemic: Panel evidence from 12 countries

Yann Algan, Daniel Cohen, Eva Davoine, Martial Foucault, and Stefanie Stantcheva

PNAS October 5, 2021 118 (40) e2108576118; <https://doi.org/10.1073/pnas.2108576118>

Significance

During the COVID-19 pandemic, support for nonpharmaceutical interventions (NPIs) and compliant behavior changed substantially over time. Using a large-scale, longitudinal, and representative survey for 12 countries from March to December 2020 (n = 54,000), combined with experimental data, we show that trust in scientists is the critical determinant of societies' resilience in their fight against the pandemic. Yet, this trust has eroded dramatically in some countries such as France. Individuals and countries for which trust in scientists has declined have experienced fading support for and compliance with NPIs. In countries where trust in government is low, the independence of scientists and scientific institutions is essential to obtain citizen's support for measures necessary to protect public health.

Abstract

This article analyzes the specific and critical role of trust in scientists on both the support for and compliance with nonpharmaceutical interventions (NPIs) during the COVID-19 pandemic. We exploit large-scale, longitudinal, and representative surveys for 12 countries over the period from March to December 2020, and we complement the analysis with experimental data. We find that trust in scientists is the key driving force behind individual support for and compliance with NPIs and for favorable attitudes toward vaccination. The effect of trust in government is more ambiguous and tends to diminish support for and compliance with NPIs in countries where the recommendations from scientists and the government were not aligned. Trust in others also has seemingly paradoxical effects: in countries where social trust is high, the support for NPIs is low due to higher expectations that others will voluntarily social distance. Our individual-level longitudinal data also allows us to evaluate the

effects of within-person changes in trust over the pandemic: we show that trust levels and, in particular, trust in scientists have changed dramatically for individuals and within countries, with important subsequent effects on compliant behavior and support for NPIs. Such findings point out the challenging but critical need to maintain trust in scientists during a lasting pandemic that strains citizens and governments.

Prehospital & Disaster Medicine

Volume 36 - Issue 5 - October 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 150 September 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/150/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

13 October 2021 Volume 288 Issue 1960

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 198 Pages e1-e34, 1-358 (September 2021)

<https://www.sciencedirect.com/journal/public-health/vol/198/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 14, Issue 1, April 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 136 Issue 5, September/October 2021

<https://journals.sagepub.com/toc/phrg/136/5>

[Reviewed earlier]

Qualitative Health Research

Volume 31 Issue 10, August 2021

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

Research Ethics

Volume 17 Issue 4, October 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 16 Oct 2021]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

[No new digest content identified]

Risk Analysis

Volume 41, Issue 9 Pages: 1497-1735 September 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 16 Oct 2021]

Original Research

[Prevalence, Trends and Conditions for the DTP3 Vaccine: A 25-Year Historical Perspective](#)

Araújo Veras AAC, Arruda Vidal S, Costa de Macêdo V, de Carvalho Lima M, Cabral de Lira PI, da Fonseca Lima EJ, Batista Filho M

Risk Management and Healthcare Policy 2021, 14:4301-4310

Published Date: 14 October 2021

Science

Volume 374| Issue 6565| 15 Oct 2021

<https://www.science.org/toc/science/current>

Special issue - Mass Incarceration

[New issue; No digest content identified]

Science Translational Medicine

Volume 13| Issue 615| 13 Oct 2021

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Social Science & Medicine

Volume 285 September 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/285/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 16 Oct 2021]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 43 September–October 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/43/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 10 Pages: i-iv, 1139-1323 October 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

RESEARCH ARTICLES

[Acceptance and willingness to pay for COVID-19 vaccines among pregnant women in Vietnam](#)

Long Hoang Nguyen, Men Thi Hoang, Lam Duc Nguyen, Ly Thi Ninh, Ha Thi Thu Nguyen, Anh Duy Nguyen, Linh Gia Vu, Giang Thu Vu, Linh Phuong Doan, Carl A. Latkin, Bach Xuan Tran, Cyrus S.H. Ho, Roger C.M. Ho

Pages: 1303-1313

First Published: 09 August 2021

Vaccine

Volume 39, Issue 41 Pages 6015-6182 (1 October 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/41>

Discussion Full text access

[Standardizing shared vaccination responsibilities among specialists to improve vaccination rates of immunosuppressed patients](#)

Shubha Bhat, Freddy Caldera, Francis A. Farraye

Pages 6015-6016

Discussion Full text access

[The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action](#)

John G. Rizk, Charles E. Barr, Youssef Rizk, John C. Lewin
Pages 6017-6018

Research article Full text access

[Prenatal maternal COVID-19 vaccination and pregnancy outcomes](#)

Tamar Wainstock, Israel Yoles, Ruslan Sergienko, Eyal Sheiner
Pages 6037-6040

Research article Abstract only

[Factors affecting non-coverage of measles-rubella vaccination among children aged 9–59 months in Tanzania](#)

Abdallah Mkopi, Sally Mtenga, Charles Festo, Grace Mhalu, ... Honorati Masanja
Pages 6041-6049

Research article Open access

[Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use](#)

Abraham Palache, Steven Rockman, Beverly Taylor, Meral Akcay, ... Paula Barbosa
Pages 6081-6087

Research article Full text access

[The impact of COVID-19 vaccination delay: A data-driven modeling analysis for Chicago and New York City](#)

Vinicius V.L. Albani, Jennifer Loria, Eduardo Massad, Jorge P. Zubelli

Research article Open access

[Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence](#)

Keiko Kunitoki, Masafumi Funato, Makiko Mitsunami, Takahiro Kinoshita, Michael R. Reich
Pages 6104-6110

Research article Full text access

[A hub-and-spoke design for ultra-cold COVID-19 vaccine distribution](#)

Xinglu Xu, Mark D. Rodgers, Weihong (Grace) Guo
Pages 6127-6136

Vaccines

<https://www.mdpi.com/journal/vaccines>

Open Access Article

[Cognitive Factors Influencing COVID-19 Vaccination Intentions: An Application of the Protection Motivation Theory Using a Probability Community Sample](#)

by [Kwok Kit Tong](#) et al.

Vaccines 2021, 9(10), 1170; <https://doi.org/10.3390/vaccines9101170> - 12 Oct 2021

Abstract

COVID-19 vaccines, as one of the effective ways of dealing with the COVID-19 pandemic, can lower COVID-19 risk and protect against severe disease and death; however, substantial individual differences in vaccination intentions have hindered the realization of a high vaccination rate among the [..

Open Access Article

Determinants of COVID-19 Vaccine Hesitancy in Portuguese-Speaking Countries: A Structural Equations Modeling Approach

by [Álvaro Francisco Lopes de Sousa](#) et al.

Vaccines 2021, 9(10), 1167; <https://doi.org/10.3390/vaccines9101167> (registering DOI) - 12 Oct 2021

Abstract

COVID-19 vaccine hesitancy (VH) has caused concerns due to the possible fluctuations that may occur directly impacting the control of the pandemic. In this study, we aimed to estimate the prevalence and factors associated with COVID-19 VH in Portuguese-speaking countries. We developed a [...

Open Access Article

Correlates of COVID-19 Vaccine Acceptance, Hesitancy and Refusal among Employees of a Safety Net California County Health System with an Early and Aggressive Vaccination Program: Results from a Cross-Sectional Survey

by [Nicole M. Gatto](#) et al

Vaccines 2021, 9(10), 1152; <https://doi.org/10.3390/vaccines9101152> - 09 Oct 2021

Abstract

Since health professionals provide frontline care to COVID-19 patients, information on vaccine acceptance among healthcare workers is needed. We developed and implemented an anonymous internet-based cross-sectional survey with direct solicitation among employees of a safety net health system. Items queried demographic and health-related [...]

Value in Health

October 2021 Volume 24 Issue 10 p1391-1542

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....
.....

medRxiv

medRxiv is a free online archive and distribution server for complete but [unpublished manuscripts](#) (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 16 Oct 2021]

Selected Content

Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2

Manuela Di Fusco, Mary M Moran, Alejandro Cane, Daniel Curcio, Farid Khan, Deepa Malhotra, Andy Surinach, Amanda Miles, David Swerdlow, John M McLaughlin, Jennifer L Nguyen
medRxiv 2021.10.12.21264707; doi: <https://doi.org/10.1101/2021.10.12.21264707>

Effects of Side-Effect Risk Framing Strategies on COVID-19 Vaccine Intentions in the United States and the United Kingdom: A Randomized Controlled Trial

Nikkil Sudharsanan, Caterina Favaretti, Violetta Hachaturyan, Till Baernighausen, Alain Vandormael
medRxiv 2021.10.12.21264877; doi: <https://doi.org/10.1101/2021.10.12.21264877>

Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021

Barbara A Cohn, Piera M Cirillo, Caitlin C Murphy, Nickilou Y Krigbaum, Arthur W Wallace
medRxiv 2021.10.13.21264966; doi: <https://doi.org/10.1101/2021.10.13.21264966>

Breastfeeding infants receive neutralizing antibodies and cytokines from mothers immunized with a COVID-19 mRNA vaccine

Vignesh Narayanaswamy, Brian Pentecost, Corina N Schoen, Dominique Alfandari, Sallie S Schneider, Ryan Baker, Kathleen F Arcaro
medRxiv 2021.10.12.21264890; doi: <https://doi.org/10.1101/2021.10.12.21264890>

A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients

Andrew H. Karaba, Xianming Zhu, Tao Liang, Kristy H. Wang, Alex G. Rittenhouse, Olivia Akinde, Yolanda Eby, Jessica E. Ruff, Joel N. Blankson, Aura T. Abedon, Jennifer L. Alejo, Andrea L. Cox, Justin R. Bailey, Elizabeth A. Thompson, Sabra L. Klein, Daniel S. Warren, Jacqueline M. Garonzik-Wang, Brian J. Boyarsky, Ioannis Sitaras, Andrew Pekosz, Dorry L. Segev, Aaron A.R. Tobian, William A. Werbel
medRxiv 2021.08.11.21261914; doi: <https://doi.org/10.1101/2021.08.11.21261914>

Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines

Vivek Naranbhai, Wilfredo F. Garcia-Beltran, Christina C. Chang, Cristhian Berrios Mairena, Julia C. Thierauf, Grace Kirkpatrick, Maristela L. Onozato, Ju Cheng, Kerri J. St. Denis, Evan C. Lam, Clarety Kaseke, Rhoda Tano-Menka, Diane Yang, Maia Pavlovic, Wendy Yang, Alexander Kui, Tyler E. Miller, Michael G. Astudillo, Jennifer E. Cahill, Anand S. Dighe, David J. Gregory, Mark C. Poznansky, Gaurav D. Gaiha, Alejandro B. Balazs, A. John Iafrate
medRxiv 2021.07.18.21260732; doi: <https://doi.org/10.1101/2021.07.18.21260732>

The impact of mandatory COVID-19 certificates on vaccine uptake: Synthetic Control Modelling of Six Countries

Melinda C. Mills, Tobias Rüttenauer
medRxiv 2021.10.08.21264718; doi: <https://doi.org/10.1101/2021.10.08.21264718>

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

Lisa M. Dunkle, Karen L. Kotloff, Cynthia L. Gay, Germán Áñez, Jeffrey M. Adelglass, Alejandro Q. Barrat Hernández, Wayne L. Harper, Daniel M. Duncanson, Monica A. McArthur, Diana F. Florescu, R. Scott McClelland, Veronica Garcia-Fragoso, Robert A. Riesenberger, David B. Musante, David L. Fried, Beth E. Safirstein, Mark McKenzie, Robert J. Jeanfreau, Jeffrey K. Kingsley, Jeffrey A. Henderson, Dakota C. Lane, Guillermo M. Ruíz-Palacios, Lawrence Corey, Kathleen M. Neuzil, Robert W. Coombs,

Alex L. Greninger, Julia Hutter, Julie A. Ake, Katherine Smith, Wayne Woo, Iksung Cho, Gregory M. Glenn, Filip Dubovsky, for the 2019nCoV-301 Study Group
medRxiv 2021.10.05.21264567; doi: <https://doi.org/10.1101/2021.10.05.21264567>

* * * *

Think Tanks et al

Brookings [to 16 Oct 2021]

<http://www.brookings.edu/>

Report

Amid the pandemic, Black and Latino men have experienced the largest drop in life expectancy

Andre M. Perry, Ariel Gelrud Shiro, Anthony Barr, and Carl Romer

Monday, October 11, 2021

Center for Global Development [to 16 Oct 2021]

<http://www.cgdev.org/page/press-center>

Accessed 16 Oct 2021

Four Pandemic Asks for IDA20 Replenishment at the World Bank

October 13, 2021

The World Bank's International Development Association (IDA), the largest single source of concessional financing for development in lower-income countries, is under-utilized in the world's fight against pandemics, and can deploy its resources and expertise to play a much more significant role in the COVID-19 response and beyond as part of its upcoming replenishment, known as IDA20.

[Amanda Glassman](#)

The Roots of Policy Incoherence: Domestic Policy, Global Public Goods, and International Development

Publication

October 12, 2021

Governments make policy to affect three domains: domestic outcomes, outcomes in foreign countries, and shared global challenges. This note sets out how the conceptual and analytical incoherence of policy set in developed countries across these three domains undermines their own effectiveness—most notably on international development and shared global challenges.

Chatham House [to 16 Oct 2021]

<https://www.chathamhouse.org/>

Accessed 16 Oct 2021

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 16 Oct 2021

Transcript

Allied Infrastructure Strategy in the Indo-Pacific

October 15, 2021

Transcript

What Next? Looking Beyond the Covid-19 Summit

October 14, 2021

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

[No new digest content identified]

ODI [Overseas Development Institute] [to 16 Oct 2021]

<https://odi.org/en/publications/>

Publications

What MDBs (and their shareholders) can do for vaccine equity

06 October 2021

In late 2020 the World Bank and the Asian Development Bank (AsDB) announced large-scale financing packages to help the rollout of Covid-19 vaccines in low- and middle-income countries. But despite the urgency of doing this to bring the global pandemic to an end, the uptake of these financing packages has so far been slow. Why are committed funds sitting idle at the same time that vaccination programmes are a priority in many countries battling new waves of Covid-19 infections? And at the same time as many activists and world leaders call on G7 leaders to ramp up their contributions to the global vaccination effort?

In this long-read we review some of the factors and bottlenecks that can plausibly explain this low uptake of MDB financing for vaccine purchases from governments in low- and middle-income countries. More importantly, we outline what management and shareholders of MDBs should do to ramp up the use of these financing facilities or deploy resources to support the health response against Covid-19. The fundamental issue has been between the country-based lending model of MDBs and the need to finance and procure a global public good (a low-cost vaccine). MDBs thus need a clearer mandate and dedicated grant financing for global public goods, including vaccine procurement.

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute , [PATH](#), and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*